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CHAPTER I 
INTRODUCTION 
RATIONALE OF NOVEL DRUG DELIVERY SYSTEM1,5,7,8,9: 
 Most of the drugs introduced to clinical medicine exert their effects by interactive 
interference with cell and cell membrane related structure and function through concentration 
dependent reversible interactions at specific receptor site. 
 Presently, conventional dosage forms (tablets, capsules, pills, injections) are primarily 
prescribed pharmaceutical products and are available over-the-counter. 
 To achieve and maintain the concentration of a administered drug within therapeutically 
effective range, it is often necessary to take drug dosage several times and this results in a 
fluctuating drug levels in plasma8. 
 The goal in designing novel drug delivery system is to reduce the frequency of dosing of 
to increase effectiveness of the drug by localization at the site of action, reducing dose required 
or providing uniform drug delivery and the other criteria is should deliver the active entity to the 
site of action, thereby minimizing or eliminating side effects5,7. 
 The fluctuations produced by the conventional drug delivery system can be overcome by 
using several approaches. They are: 
1. Targeted delivery 
2. Sustained release 
3. Controlled release  
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4. Prolonged release 
5. Modulated release 
       
The above figure shows the differences between conventional drug delivery system and the 
sustained/controlled drug delivery system. From the figure, it was concluded that fluctuations in 
the drug level is obtained in conventional delivery also the blood level reaches the toxic level. 
But as in the case of sustained drug delivery system, the sustained/controlled drug delivery 
system maintains the drug level below its toxic range also reducing the multiple – dosing1. It 
should be emphasized that the plasma level of a drug should be maintained within the safe 
margin and effective range, for this proper and calculated dose of the drug need to be given at 
different time intervals by conventional dosage forms7. 
 
 
    
3 
 
1. Targeted drug delivery systems, TDDS: 
It refers to the systemic administration of a drug-carrier with the goal of delivering the 
drug to predetermined target in therapeutic concentration, while restricting its access to 
non-target normal cellular linings, thus minimizing therapeutic index. 
2. Sustained release systems: 
It is developed to maintain therapeutic blood or tissue levels of the drug for an extended 
period of time which is concentration dependent. 
3. Controlled release systems: 
Zero-order release constituted drug release from the dosage form that is independent of 
the amount of drug in the delivery system i.e. concentration independent and constant 
release time. 
4. Prolonged release systems: 
The release of the delivery system is attained for prolonged period of time i.e. for several 
weeks or even months. 
5. Modulated release systems: 
It implies use of a drug delivery device that releases the drug at a variable rate controlled 
by environmental conditions, biofeedback, sensor input or an external control device. 
Controlled and targeted delivery is one of the most enviable requirements from a carrier, 
which involves the multidisciplinary site- specific or targeted approach. Targeted drug delivery 
systems includes, liposomes, niosomes, nanoparticles, microspheres, resealed erythrocytes etc. 
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The advantages of novel drug delivery systems is as follows5,7,8: 
 Controlled/sustained delivery of active agent at predetermined rate 
 Maintenance of optimal and effective drug level for prolonged duration 
 Reduction of untoward effects 
 Increase in patient compliance 
 Reduction in frequency of dosing 
 Delivery of drug in the vicinity of site of action 
 More efficient utilization of active agent 
 Enhancement of bioavailability 
 
Hence, by the above considerations, a novel drug delivery is needed to conquer the  
problems associated with conventional formulations. 
TARGETED DRUG DELIVERY SYSTEMS5: 
It implies for selective and effective localization of pharmacologically active moiety at 
predetermined (preselected) target in therapeutic concentration, while restricting its access to 
non-target normal cells. 
 The colloidal drug delivery systems such as liposomes, niosomes, nanoparticles enhances 
the bioavailability of drugs which is shown in fig.2. In general, these colloidal carrier systems 
have the nanometric size range, in this size range the liver cannot uptake the drug from the 
delivery system and are not metabolized by the liver. Hence, the drug will be circulated in the 
blood levels for prolonged period of time and delivers the drug at constant time which will 
reduces the toxicity. 
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Fig.2 Various mechanisms of enhancement of drug bioavailability in the presence of lipids 
 
This may be achieved by using carrier systems, where reliance is placed on exploiting both 
intrinsic pathway that these carriers follow, and the bioprotection that they can offer to drugs 
during transit through the body. 
The various carrier systems used for targeted drug delivery are as follows: 
1. Colloidal carriers: 
A) Vesicular systems 
• Liposomes 
• Niosomes 
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• Pharmacosomes 
• Virosomes 
• Immunoliposomes 
B) Microparticulate systems 
• microparticles 
• nanoparticles 
• magnetic microspheres 
• albumin microspheres 
• nanocapsules 
• Solid lipid nanoparticles 
2. Cellular carriers  
• Resealed arythrocytes 
• Serum albumin 
• Antibodies 
• Platelest 
• Leukocytes 
3. Supramolecular delivery systems 
• Micelles  
• Liquid crystals  
• Lipoproteins 
4. Polymer based systems 
• Signal sensitive 
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• Micoadhesive 
• Biodegradable 
• Bioerodablie 
• Soluble synthetic polymeric carriers 
5. Macro molecular carriers 
Proteins; Glycoproteins; Articificial viral envelops 
Glycosylated water soluble polymers  
Monoclonal antibodies 
Toxins  
Leptons 
Polysaccharides 
 
NANOTECHNOLOGY- INTRODUTION 20: 
 Nanotechnology is the science of that deals with the particle size in nanometer 
range. 
 Produces new career therapies, drug delivery systems and biomaterial for implant 
or prosthesis. 
 Small colloidal particles that are made of non-biodegradable and biodegradable 
polymers and the diameter is around 200 nm. 
 Nano-device are some where 100 to 10000 times smaller than the human cells and 
are similar in size of biological molecules (enzymes and receptors) 
 This offers to study and interact with normal as well as cancer cells 
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NANOPARTICLES5,6,7,8,19,20,21, : 
Nanoparticles are solid polymeric, submicronic colloidal system range between 5-300nm 
consisting of macromolecular substances that vary in size 10nm to 1000nm. The drug of interest 
is dissolved, entrapped adsorbed, attached or encapsulated into the nanoparticle matrix.  
Depending upon the method of preparation, nanoparticle, nanosphere or nanocapsule can 
be obtained with different properties and release characteristics for the encapsulated therapeutic 
agent.  
1. Nanosphere are matrix system in which drug is physically and uniformly dispersed 
throughout, then particles prepared by using different polymers such as polyalkylcyanoacrylate 
& poly lactides or they can be solid lipid nanosphere prepared by using lipids like dipalmitoyl – 
phosphatidyl choline.  
2. Nanocapsule are ultrafine vesicular system with a diameter less than 1 µm in which the 
drug is confined to a cavity surrounded by a unique polymer membrane and having aqueous or 
oily core containing drug substances.  
Nanoparticles holds much interest, because in this range materials can have different and 
enhanced properties compared with the same materials of a larger size due to the following two 
major principle factors. The increased surfaces are of quantum effect. These factors can enhance 
properties such as reactivity, strength, electrical characteristics & in vivo behavior and a much 
greater surface area per unit mass compared with the larger particles leading to greater reactivity.  
The advantages of using nanoparticles loaded with drugs, because of their small size can 
penetrate through small capillaries and are taken up by cells and allow the drug release at right 
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rate and dose at specific sites in the body for a certain time to release the accurate delivery, 
which enhances the therapeutic effect and reduces the toxicity and side effects. The use of 
biodegradable materials for nanoparticles preparation allows sustained release within the target 
site over a period of days or even weeks. 
 
Types of NPS as carrier for drug & diagnostic agents 
• Polymeric NPS 
• Nanosuspensions and nanocrystals 
• Polymeric micelles 
• Ceramic NPS 
• Liposome’s 
• Fullerenes and dendrimers 
• SLN (Solid lipid nanoparticles) 
• Magnetic nanoparticles 
• Nanoshells coated with gold 
• Nanomers and carbon nanotubes 
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Fig. 3 represents the structure various nanoparticulate systems 
Polymeric nanoparticles: 
It consists of drug dispersed in an amorphous form within a polymer matrix. Examples of 
polymers include poly (alkyl cyanoacrylates), poly (glycolic acid) etc. 
Nanosuspensions/ Nanocrystals: 
Nanocrystals are crystals of poorly water-soluble drug in nanosize which when dispersed 
in water produce nanosuspension. Nanocrystalline drug suspensions have an advantage of higher 
loading capacity up to 90 % of the crystalline particle. 
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Polymeric micelles: 
 Polymeric micelles are nanosized core/shell assemblies of amphiphilic block copolymers 
that are suitable for the delivery of hydrophobic and amphiphilic agents. 
Liposomes: 
 Liposomes are spherical microscopic vesicles composed of one or more concentric lipid 
bilayers, separated by water or aqueous buffer compartments with a diameter ranging from 25 
nm to 10000 nm. 
Solid lipid nanoparticles: 
 Melt-emulsified nanoparticles based on lipids are solid at room temperature. 
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CHAPTER II 
SOLID LIPID NANOPARTICLES: A REVIEW 
Solid lipid nanoparticles are one of the novel potential colloidal carrier systems as 
alternative materials to polymers which is identical to oil in water emulsion for parenteral 
nutrition, but the liquid lipid of the emulsion has been replaced by a solid lipid (shown on fig. 4). 
They have many advantages such as good biocompatibility, low toxicity and lipophillic drugs are 
better delivered by solid lipid nanoparticles and the system is physically stable. Solid lipid 
nanoparticles may be a promising sustained – release and drug targeting system for   lipophilic 
drugs.  
                                              
Fig.4 Structure of SLN 
Solid lipid nanoparticles (SLNs) are considered to be the most effective lipid based 
colloidal carriers, introduced in early nineties. This is the one of the most popular approaches to 
improve the oral bioavailability of the poorly water soluble drugs. SLNs are in the submicron 
size range of 50-1000 nm and are composed of physiologically tolerated lipid components which 
are in solid state at room temperature. The schematic representation of different particulate drug 
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carriers such as emulsions and liposomes and their advantages are compared with SLNs in Fig. 
5. SLNs combine all the advantages of polymeric nanoparticles, fat emulsions  and liposomes. 
 
Fig. 5 A diagrammatic representation on SLN over emulsions and liposomes 
ADVANTAGES OF SOLID LIPID NANOPARTICLES5,11,14,19,21 : 
 Better control over release kinetics of encapsulated compounds 
 Engineering via size and lipid composition 
 Melting serve as trigger 
 Enhanced bioavailability of entrapped bioactive compounds 
 Chemical protection of labile incorporated compounds 
 Much easier to manufacture than biopolymeric nanoparticles 
 No special solvent required 
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 Conventional emulsion manufacturing methods applicable 
 Raw materials essential the same as in emulsions 
 Very high long-term stability 
 Application versatility 
 Can be subjected to commercial sterilization procedures 
 Can be freeze dried to form powdered formulation 
 The use of physiological lipids 
 A potential wide application spectrum (dermal, per os, intravenous)  
LIPIDS AND EMULSIFIERS USED FOR THE PREPARATION OF 
SOLID LIPID NANOPARTICLES5,11, 
A] LIPIDS: 
Triglyceride: 
 Tricaprin 
 Trilaurin 
 Trimyristin 
 Tripalmitin 
 Tristearin 
 Hydrogenated coco-glycerides 
Hard fat types: 
 Witepsol W35 
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 Witepsol H35 
 Witepsol H42 
 Witepsol E85 
 Glyceryl monostearate 
 Glyceryl behenate 
 Glyceryl palmitostearate 
 Cetyl palmitate 
 Stearic acid 
 Palmitic acid 
 Decanoicacid 
 Behenicacid 
 Acidan N12 
Emulsifiers 
 Soybean lecithin 
 Egg lecithin 
 Phosphatidylcholine 
 Poloxamer (188, 182, 407) 
 Poloxamine (908) 
 Tyloxapol  
 Span (20, 40, 60, 80) 
 Tween (20,40,60,80) 
 Polyvinylalcohol 
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Co emulsifiers 
 Sodiumcholate 
 Sodium glycocholate 
 Taurocholic acid 
 Taurodoxycholic acid 
 Butyric acid 
 
INFLUENCE OF EXCIPIENTS11,12,16, 
Formulation variables in the product quality: 
Particle size  
Alteration of the size significantly affects the physical stability, biofate of the lipid 
particles, and release rate of the loaded drug. Hence the size of the SLNs has to be controlled 
within reasonable range. Well formulated systems (liposomes, nanospheres and nanoparticles) 
should display a narrow particle size distribution in the submicron size range (as having size 
below 1µm), according to the definition of colloidal particles.  
Influence of the ingredients on product quality  
The particle size of lipid nanoparticles is affected by various parameters such as 
composition of the formulation (such as surfactant/ surfactant mixture, properties of the lipid and 
the drug incorporated), production methods and conditions (such as time, temperature, pressure, 
cycle number, equipment, sterilization and lyophilization). Large particle size is obtained at 
lower processing temperature. The hot homogenization technique gives a smaller particle size, 
generally below 500 nm, and a narrow particle size distribution as compared to cold 
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homogenization. Mean particle size as well as polydispersity index (PI) values are reported to be 
reduced at increasing homogenization pressure up to 1500 bar and number of cycles (3-7 cycles).  
Influence of the lipids  
Using the hot homogenization, it has been found that the average particle size of SLN 
dispersions is increasing with higher melting lipids. However, other critical parameters for 
nanoparticle formation will be different for the different lipids. The examples include the 
velocity of lipid crystallization, the lipid hydrophilicity (influence on self-emulsifying properties 
and the shape of the lipid crystals (and therefore the surface area)..  
Further, increasing the lipid content over 5-10% resulted in larger particles (including 
microparticles) and broader particle size distribution in most cases.  
Influence of the emulsifiers  
The concentration of the surfactant/surfactant mixture strongly affects the particle size of 
the lipid nanoparticles. In general, smaller particle sizes were observed when a higher surfactant/ 
lipid ratio was chosen. The decrease in surfactant concentration resulted in increase of particle 
size during storage.  
Surfactants decrease the surface tension between the interface of the particles causing 
portioning of the particles and thereby increasing the surface area.  
 
 
PREPARATION OF SOLID LIPID NANOPARTICLES5,10,11,12,14,19,20,21 : 
SLNs are prepared from lipid, emulsifier and water/solvent by using different methods 
and are discussed below. 
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Methods of Preparation of Solid Lipid Nanoparticles 
1.  High pressure homogenization 
  Hot homogenization 
Cold homogenization 
2. Ultrasonication/high speed homogenization 
Probe ultrasonication 
Bath ultrasonicatioin 
3.  Solvent evaporation method 
4. Solvent emulsification-diffusion method 
5.  Supercritical fluid method 
6.  Microemulsion based method 
7. Spray drying method 
8. Double emulsion method 
9. Precipitation technique 
 
1. High pressure homogenization (HPH): 
It is a reliable and powerful technique, which is used for the production of SLNs. High 
pressure homogenizers push a liquid with high pressure (100–2000 bar) through a narrow gap (in 
the range of a few microns). The fluid accelerates on a very short distance to very high velocity 
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(over 1000 km/h). Very high shear stress and cavitation forces disrupt the particles down to the 
submicron range. Generally 5-10% lipid content is used but up to 40% lipid content has also 
been investigated. 
Two general approaches of HPH are hot homogenization and cold homogenization; work 
on the same concept of mixing the drug in bulk of lipid melt. 
A). Hot homogenization: 
Hot homogenization is carried out at temperatures above the melting point of the lipid 
and can therefore be regarded as the homogenization of an emulsion. A preemulsion of the drug 
loaded lipid melt and the aqueous emulsifier phase (same temperature) is obtained by high-shear 
mixing device. HPH of the pre-emulsion is carried out at temperatures above the melting point of 
the lipid. In general, higher temperatures result in lower particle sizes due to the decreased 
viscosity of the inner phase. However, high temperatures increase the degradation rate of the 
drug and the carrier. Increasing the homogenization pressure or the number of cycles often 
results in an increase of the particle size due to high kinetic energy of the particles. 
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Fig. 6 Solid lipid nanoparticles preparation by hot homogenization process 
B). Cold homogenization: 
Cold homogenization has been developed to overcome various problems associated with 
hot homogenization such as: Temperature-induced drug degradation, drug distribution into the 
aqueous phase during homogenization, Complexity of the crystallization step of the 
nanoemulsion leading to several modifications and/or supercooled melts (62). In this technique 
the drug containing lipid melt is cooled, the solid lipid ground to lipid microparticles and these 
lipid microparticles are dispersed in a cold surfactant solution yielding a pre-suspension. Then 
this pre-suspension is homogenized at or below room temperature, the cavitation force is strong 
enough to break the lipid microparticles directly to solid lipid nanoparticles. 
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Fig. 7 Solid lipid nanoparticles preparation by cold homogenization process. 
 
Advantages : 
 Low capital cost  
 Demonstrated at lab scale 
Disadvantages : 
 Energy intensive process 
 Demonstrated at lab scale Biomolecule damage 
 Polydisperse distributions 
 Unproven scalability 
 
2. Ultrasonication/high speed homogenization: 
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SLNs are also prepared by ultrasonication or high speed homogenization techniques. For 
smaller particle size combination of both ultrasonication and high speed homogenization is 
required. 
Advantages:  
 Reduced shear stress  
Disadvantages: 
 Potential metal contamination  
 Physical instability like particle growth upon storage  
3. Solvent evaporation: 
SLNs are also prepared by solvent evaporation method. The lipophilic material is 
dissolved in a water-immiscible organic solvent (e.g. cyclohexane) that is emulsified in an 
aqueous phase. Upon evaporation of the solvent, nanoparticles dispersion is formed by 
precipitation of the lipid in the aqueous medium by giving the nanoparticles of 25 nm mean size. 
The solution was emulsified in an aqueous phase by high pressure homogenization. The organic 
solvent was removed from the emulsion by evaporation under reduced pressure (40–60 mbar). 
Advantages: 
 Scalable  
 Mature technology 
 Continous process 
 Commercially demonstrated 
Disadvantages: 
 Extremely energy intensive process 
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 Polydisperse distributions 
 Biomolecule damage 
 
4.  Solvent emulsification-diffusion method: 
 The particles with average diameters of 30-100 nm can be obtained by this technique. 
Avoidance of heat during the preparation is the most important advantage of this technique. 
                        
 Fig. 8 Systematic representation for emulsification-diffusion method 
5. Supercritical fluid method: 
This is an alternative method of preparing SLNs by particles from gas saturated solutions 
(PGSS).  
Advantages  
 Avoid the use of solvents 
 Particles are obtained as a dry powder, instead of suspensions 
 Mild pressure and temperature conditions  
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 Carbon dioxide solution is the good choice as a solvent for this method  
6. Microemulsion based method: 
This method is based on the dilution of microemulsions. As microemulsions are two-
phase systems composed of an inner and outer phase (e.g. o/w microemulsions). They are made 
by stirring an optically transparent mixture at 65-70°C which typically composed of a low 
melting fatty acid (e.g. stearic acid), an emulsifier (e.g. polysorbate 20), co-emulsifiers (e.g. 
butanol,) and water. The hot microemulsion is dispersed in cold water (2-3°C) under stirring. 
SLN dispersion can be used as granulation fluid for transferring in to solid product (tablets, 
pellets) by granulation process, but in case of low particle content too much of water needs to be 
removed. High-temperature gradients facilitate rapid lipid crystallization and prevent 
aggregation. Due to the dilution step; achievable lipid contents are considerably lower compared 
with the HPH based formulations.       
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Fig. 9 Microemulsion method 
 Advantages: 
 Low mechanical energy input 
 Theoretical stability 
Disadvantages: 
 Extremely sensitive to change  
 Labor intensive formulation work 
 Low nanoparticle concentrations 
7. Spray drying method: 
It is an alternative technique to the lyophilization process. This recommends the use of 
lipid with melting point more than 70 c. The best results were obtained with SLN concentration 
of 1% in a solution of trehalose in water or 20% trehalose in ethanol-water mixture. 
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8. Double emulsion method: 
 Here the drug is encapsulated with a stabilizer to prevent the  partitioning of drug in  to 
external water phase during solvent evaporation in the external water phase of w/o/w double 
emulsion. 
9. Precipitation method: 
The glycerides are  dissolved in an organic solvent (e.g. chloroform) and the solution will 
be emulsified in an aqueous phase. After evaporation of the organic solvent the lipid will be 
precipitated forming nanoparticles.  
 
SECONDARY PRODUCTION STEPS 11,14,22,23 : 
Freeze drying  
Lyophilization is a promising way to increase the chemical and physical stability over 
extended periods of time. Lyophilization had been required to achieve long term stability for a 
product containing hydrolysable drugs or a suitable product for per-oral administration. 
Transformation into the solid state would prevent the Oswald ripening and avoid hydrolytic 
reactions.  
In case of freeze drying of the product, all the lipid matrices used, form larger solid lipid 
nanoparticles with a wider size distribution due to presence of aggregates between the 
nanoparticles. The conditions of the freeze drying process and the removal of water promote the 
aggregation among SLNs. An adequate amount of cryoprotectant can protect the aggregation of 
solid lipid nanoparticles during the freeze drying process.  
Sterilization  
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Sterilization of the nanoparticles is desirable for parenteral administration and 
autoclaving which is applicable to formulations containing heat-resistant drugs. Effects of 
sterilization on particle size have been investigated and it was found to cause a distinct increase 
in particle size. 
Spray drying  
Spray drying might be an alternative procedure to lyophilization in order to transform an 
aqueous SLN dispersion into a dry product. This method has been used scarcely for SLN 
formulation, although spray drying is cheaper as compared to lyophilization.  
 The lipids with melting points at temperature >70°C had been recommended for spray 
drying.  
 
DRUG INCORPORATION MODELS AND TYPES OF SLN13: 
 factors affecting loading capacity of a drug in lipid are  
1. Solubility of drug in lipid melt 
2. Miscibility of drug melt and lipid melt 
3. Chemical and physical structure of solid matrix lipid 
4. Polymorphic state of lipid material 
 
 
 
 
 
 
    
28 
 
Drug incorporation models are as follows: 
 
    
 
Fig. 10 Drug incorporation models 
 Solid solution model: 
Drug is molecularly dispersed in lipid matrix when SLN is prepared by cold 
homogenization 
 Drug-enriched shell model: 
A solid lipid core forms upon recrystalization temperature of the lipid is reached. 
 Drug-enriched core model: 
Cooling the nanoemulsion leads to a supersaturation of the drug which is dissolved in the 
lipid melt leads to recrystallization of the lipid. 
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POSSIBLE PROBLEMS IN SLN PREPARATION AND SLN 
PERFORMANCE11,13,21: 
1. High pressure-induced drug degradation: 
 It has been shown to decrease the molecular weight of polymers. High stress has been 
assumed to be the major cause and evidence of free radical formation was reported. But it’s not a 
serious problem for majority of the drugs. 
2. Lipid crystallization and drug incorporation: 
The following four key aspects should be considered: 
2. A) Supercooled melts: 
 The main reason for the formation of supercooled melts is the size dependence of 
crystallization processes. The tendency of the formation of supercooled melts increases with 
decreasing droplet size. It is therefore necessary to proof the solid state of the lipid by 
appropriate analytical techniques ( NMR, X-ray or DSC ). 
2. B) Lipid modification: 
 The crystallized lipid may be present in several modifications of the crystal lattice. 
During storage, rearrangement of crystal might occur in favor of thermodynamically stable 
configurations and resulted in expulsion of drug. The utilization of higher drug-loading capacity 
in unstable configurations prevents lipid modification during storage. 
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2. C) Particle shape: 
 The shape of lipid nanoparticles may significantly differ from a sphere, lipids prefer to 
crystallize in the platelet form. This can be overcome by increasing the surfactant concentration. 
2. D) Gelation phenomena: 
 The transformation of low-viscosity SLN dispersion into a viscous gel is known as 
gelation phenomena. It can be prevented by adding co-emulsifying surfactants with high 
mobility ( eg. Glycocholate). 
3. Coexistence of several colloidal species: 
 Unstable drugs will hydrolyze rapidly in contact with water and the distribution 
equilibrium of the drug between the different environments will be distorted. This can be 
overcome by increasing the matrix viscosity. 
ANALYTICAL METHODS FOR CHARACTERIZATION10,11,12,13,14,19,21,23 : 
In order to develop a drug product of high quality, a precise physicochemical characterization  
 
of the SLNs is necessary. Characterization of solid lipid nanoparticles is a serious challenge due  
 
to the small size of the particles and complexity of the system. Various parameters need to be  
 
considered as: 
 
1. Particle size measurement: 
Particle size may be determined by photon correlation spectroscopy (PCS), 
transmission electron microscopy (TEM), scanning electron microscopy (SEM), atomic force 
microscopy (AFM), scanning tunneling microscopy (STM), freeze fracture electron 
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microscopy (FFEM) and laser diffraction (LD). PCS is a good tool for particle size 
measurement as it covers a size range from few nanometers to 3 µm but unable to cover 
larger microparticles. This can be overcome by using laser diffraction (LD).  
2.  Measurement of zeta potential: 
 
Zeta potential of SLN is measured by photon correlationspectroscopy (PCS) using 
Malvern Zetasizer. The zetasizer measures the zeta potential based on the Smoluchowski 
equation. 
3. Entrapment efficiency: 
 
The amount of drug incorporated is determined after separation of the free drug and solid 
lipids from the aqueous medium and the separation is carried out by ultra-centrifugation, 
centrifugation filtration or gel permeation chromatography. Analysis is performed by              
UV-  spectrophotometry or by HPLC. 
 
4. Stability studies 
 
Drug loaded SLNs are stored at 25 °C for 6 months and average size and entrapment 
efficiency are determined. 
 
5. Effect of sterilization 
To see the effect of sterilization on particle size, zeta potential and entrapment efficiency, 
blank and drug dispersions are autoclaved at 121 °C for 20 minutes. 
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6. Characterization by differential scanning calorimetry 
Differential scanning calorimetry (DSC) (yields information on melting behavior and 
crystallization behavior of solid and liquid constituents of the particles) are performed. 
 
7. Powder X-ray diffractometry (PXRD) 
PXRD studies are performed in order to indentify the crystallinity behavior of the SLN. 
 
8. In-vitro and ex-vivo methods for the assessment of drug release from SLN 
8. A) In-vitro drug release: 
I) Dialysis tubing 
The SLN dispersion is placed in prewashed dialysis tubing which can be hermetically 
sealed. The dialysis sac is then dialyzed against a suitable dissolution medium at room 
temperature; the samples are withdrawn from the dissolution medium at suitable 
intervals, centrifuged and analyzed for drug content using a suitable analytical method.  
8. B) Reverse dialysis 
In this technique a number of small dialysis sacs containing 1 ml of dissolution medium 
are placed in SLN dispersion. The SLNs are then displaced into the dissolution medium. The 
direct dilution of the SLNs is possible with this method. 
 
8. C) Franz diffusion cell 
The solid lipid nanoparticle dispersion is placed in the donor chamber of a Franz 
diffusion cell fitted with a cellophane membrane. The dispersion is then dialyzed against a 
suitable dissolution medium at room temperature; the samples are withdrawn from the 
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dissolution medium at suitable intervals and analyzed for drug content. The maintenance of sink 
condition is essential. 
 
9. Ex-vivo model for determining permeability across the gut 
The jejunum 20–30 cm distal from the pyloric sphincter was used. The mucosal side was 
bathed with ringer buffer and the SLN were placed on the mucosal side, dispersed in ringer 
containing the paracellular transporter sodium fluorescein confirming for tissue integrity. 
 
10. Pharmacokinetic analysis 
Serum concentration versus time data for drug in individual rats is analyzed by non-
compartmental estimations. Relative bioavailability, Cmax, Tmax, AUC and MRT can be 
estimated. 
 
ADMINISTRATION ROUTES OF SLN10,11,12,13,14,21,23: 
The various administration routes of SLN is as follows: 
1. Parenteral administration: 
 Peptide and proteins drugs are usually available for parenteral use in the market. Since 
their conventional oral administration is not possible due to enzymatic degradation in GI tract. 
Parenteral application of SLN reduces the possible side effects of drug incorporated with the 
increased bioavailability. These systems are very suitable for drug targeting. 
2. Oral administration: 
 Controlled release behavior of SLNs is reported to enable the bypass of gastric and 
intestinal degradation of the encapsulated drug, and their possible uptake and transport through 
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the intestinal mucosa. However, the assessment of the stability of colloidal carriers in GI fluids is 
essential in order to predict their suitability for oral administration. 
3. Rectal administration: 
 When rapid pharmacological effect is required, in some circumstances, parenteral or 
rectal administration is preferred. This route is used for pediatric patients due to easy application. 
4. Nasal administration:  
 Due to its fast absorption and rapid onset of drug action, avoiding degradation of labile 
drugs in the GIT and insufficient transport across epithelial cell layers nasal is preferred. 
5. Respiratory delivery: 
 Nebulisation of solid lipid particles carrying anti-tubercular drugs, anti-asthmatic drugs 
and anti-cancer was observed to be successful in improving drug bioavailability and reducing the 
dosing frequency for better management of pulmonary action.  
6. Ocular administration: 
 Biocompatibility and muco-adhesive properties of SLN improve their interaction with 
ocular mucosa and prolong corneal residence time of the drug, with the aim of ocular drug 
targeting. 
7. Topical administration: 
 SLN are very attractive colloidal carrier systems for skin applications due to their various 
desirable effects on skin besides the characteristics of a colloidal carrier system. They are well 
suited for use on damaged or inflamed skin because they are based on non-irritant and non-toxic 
lipids.  
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APPLICATIONS5,10,11,12,13,14,17,18,19,21 : 
Solid lipid Nanoparticles possesses a better stability and ease of upgradability to 
production scale as compared to other colloidal drug delivery systems. This property may be 
very important for many modes of targeting. The several potential applications of SLNs 
and its pupose are given below: 
1. Cancer therapy 
 Targeting.  
 Reduced toxicity. 
 Enhanced uptake of antitumour agents. 
 Improved in invitro and invivo stability. 
2. Intracellular targeting 
 Target reticuloendothelial systems for intracellular infections. 
 Prolonged systemic circulations 
 Prolonged systemic drug effect. 
 Avoid uptake by RES. 
3. Vaccine adjuvant 
 Enhanced bioavailability. 
 Protection from gastrointestinal enzymes. 
4. Ocular delivery 
 Improved retention of drug-reduced washout. 
5. DNA delivery 
 Enhanced delivery. 
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 Significantly higher excretion levels. 
6. Oligonucleotide delivery 
 Enhanced delivery of oligonucleotide. 
7. Topical delivery 
 Antifungals and anticancers. 
8. Cosmetic application 
 Preparation of sunscreens as an active carrier agent for molecular sunscreens and 
UV blockers. 
9. Agricultural applications 
 Suitable carrier for ecologically safe pesticides. 
10. Stealth nanoparticles: 
 Target specific cells 
11. Other applications. 
 Crosses blood brain barrier. 
 Improved absorption and permeation. 
 Enzyme immunoassay. 
 Radioimaging. 
 Oral delivery of peptides.  
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CHAPTER III 
 
LITERATURE REVIEW 
 
1. Wenzhong zhou et., al studied formulation of enrofloxacin-loaded SLN and determined 
the effect of fatty acids on the characteristics and pharmacokinetics of SLN. The results 
showed that the encapsulation efficiency and loading capacity of SLN varied with fatty 
acids in the order of stearic acid > palmitic acid> tetradecanoic acid. Pharmacokinetic 
study revealed that the fatty acids increases the bioavailability of SLN. These results 
suggest that enrofloxacin-loaded SLN  are promising formulations for sustained  release 
while fatty acids had significant influences on the characteristics and performance of the 
SLN  
2.  Vinay kumar studied the effect of surface modification of solid lipid nanoparticles in 
brain targeting and concluded that surface modification of ropinirole loaded SLN with 
thiolated chitosan resulted in increased plasma levels as well as brain levels. Thiolated 
chitosan coated SLN were excellent carrier systems with good stability for brain 
targeting.  
3. Maria luisa bondi et al., studied SLN containing nimesulide SLNs carrying nimesulide 
were prepared and characterized, and the anti-proliferative effect of drug-loaded SLN 
verses free drug on HT-29 and SW-480 cell lines was here evaluated. All the obtained 
system posses colloidal size, ranging from  85 to 135 nm and negative zeta potential 
values. These systems show good loading capacity and drug release profile,and an invitro 
anti-tumour activity comparable to free drug  
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4. Waree tiyaboonchai et al., developed curcurminoids loaded SLN using a micoemulsion 
technique at 75°C. It was found that variation in the amount of ingredient had profound 
effects on the loading capacity, mean particle size and size distribution. The results 
revealed that after storage in the absence of sunlight for 6months the percentage of 
remaining curcuminoids decreases. 
5. Mansoor A. khn et al., developed the non-destructive methods of characterization of 
risperidone SLN. Uniform distribution of risperidone and compritol ATO 888 is revealed 
by near infrared-chemical imaging, and good correlation was obtained. This offers the the 
advantage over conventional method of quantitation in that multicomponent of a 
formulation can be estimated instantaneously and simultaneously after the construction of 
model.  
6. Pallavi V pople et al., investigated novel particlulate carrier system [SLN] for topical 
application of vitamin A palmitate. SLN and its gels were evaluated for particle size, drug 
release, invitro penetration, invivo skin hydration and skin irritation. In conclusion, SLN 
represent a highly effective, nonirritant carrier for cosmetic and topical preparations, 
where improved skin hydration and drug penetration it desired. 
7. Nagi A.ALHaj et al., investigated tamoxifen loaded SLN for antitumoral activity. SLN 
was characterized by DSC,TEM. Zeta potential and particle size. The results of 
characterization studies strongly support the potential application of tamoxifen loaded 
SLN as a carrier system for treating breast cancer. 
8. Anna M. Fadda et al., studied the formulation of Artemisia arborescens L essential oil 
loaded SLN for agricultural use. SLN was evaluated for Zeta potential, particle size DSC 
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and TEM. The results suggested that SLN are good potential carriers for ecological 
pesticides in agriculture. 
9. Hammam A.Mowafy et al., developed 5-fluorouracil loaded SLN for local treatment of 
colon cancer. SLN were prepared by double emulsion-solvent evaporation technique. 
From the results, it was found that SLN has a high potential to improve the uptake of 
anticancer drugs inside colon tumors. 
10. R.S.R. Murphy et al., developed etoposide-loaded SLN with glyceride lipids and then 
characterized for invitro steric stability and drug release characteristics. The study 
demonstrate that the melt emulsification and homogenization technique followed by 
spray drying is a suitable method to obtain stable powder particles further invivo use of 
SLN prolonged the circulating carriers in blood. 
11. Mahavir chougule et al., studied that methotrexate-loaded SLN for topical treatment of 
psoriasis. Findings of the studies suggest that there is significant improvement in  
therapeutic index for the treatment of psoriasis.  
12. Vivek et al., investigated the effect of lipid matrix on olanzapine-loaded SLN by hot melt 
emulsification, high-pressure homogenization technique using precirol (PRE), glyceryl 
monostearate (GMS), glyceryl tristearate (GTS), witepsol (WE), and then characterized. 
SLN surface hydrophobicity was in the following order: GTS > PRE > WE > GMS. 
13. Gande suresh et al., studied the preparation of lovastatin-loaded SLN to improve the 
bioavailability by administering duodenally to rats. Results concluded that lipophilic 
drugs like lovastatin provide controlled release of drug, and are preferred to overcome the 
bioavailability problems. 
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14. Helsagon et al., investigated the effect of surfactant surface coverage on formation and 
stability  of tween 20 stabilized tripalmitin SLN. The results suggest that surfactant 
coverage at the interface may influence crystal structure and stability of SLN via surface-
mediated crystal. 
15. Zaida Urban-Morlan et al., developed the formulation of cyclosporine-loaded SLN by 
emulsification-diffusion method and to study their physicochemical stability. 
Cyclosporine release from SLNs was relatively fast (99.60 % in 45 minutes), in 
association with a rapid dissolution due to the presence of many imperfections in lipid 
structure hence it improves the bioavailability of cyclosporine. 
16. Veerabrahma kishan at al., studied the nitrendipine loaded SLN for improving the oral 
bioavailability, using triglyceride, monoglyceride and wax. Bioavailibilty of nitrendipine 
SLN was increased three- to four- fold after intraduodenal administration compared to 
nitrendipine suspension. The obtained results are indicative of SLN as carriers for 
improving the bioavailability of nitrendipine. 
17. Keon wook et al., developed doxorubicin loaded SLN by sovent emulsification-diffusion 
method. In conclusion, SLN with small particle size, high entrapment efficiency, and 
relatively high drug loading can be obtained by this method. 
18. Doijad et al., developed cisplatin engineered SLN for the overall improvement in the 
efficacy, reduced toxicity and enhancement of therapeutic index of cisplatin. The in vitro 
result of formulated SLNs of cisplatin reveals that the drug is preferentially targeting to 
liver followed by brain and lungs. 
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19. Sedef Erdal at al., prepared indomethacin loaded SLM and evaluated. invitro drug 
release is prolonged when sucroester is used as surfactant and type of surfactant was 
found to affect the dissolution rate of indomethacin. 
20. Qing-yu Xiang et al., developed a nfor the lung-targeting delivery of dexamethasone 
acetate by intravenous administration. The concentration of drug in the lung reached a 
maximum level at 0.5 hour post dexamethasone-SLN injection, 8-fold larger area under 
the curve was achieved compared to solution. These results indicate that SLN may be 
promising lung-targeting drug carrier for dexamethasone. 
21. Elisabetta et al., investigated the effects of processing conditions on the characteristics 
of solid lipid microparticles (SLM) with a potential application as carriers for pulmonary 
administration. The results indicate that a single intratracheal administration of SLM does 
not induce a significant inflammatory airway response in rats and that the SLMs might be 
a potential carrier for encapsulated drug via the pulmonary route.  
22. Patil et al., studied the preparation of miconazole nitrate loaded SLN for topical delivery. 
The formulations could significantly increase the accumulative uptake of miconazole in 
skin over marketed gel and showed a significantly enhanced skin targeting effect. These 
results suggests that SLN formulation with skin targeting may be a promising carrier for 
topical delivery of miconazole nitrate. 
23. Santa scalia at al., developed solid lipid budesonide microparticles for controlled release 
inhalation therapy. This system was prepared by oil in water wmulsification followed by 
spray drying and evaluated in terms of morphology, particles size distribution, 
crystallinity, thermal properties, aerosol performance and dissolution release. From the 
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studies it has shown that SLM may provide a useful approach to controlled release 
respiratiory therapy. 
24. Behzad et al., conducted the study to develop SLN of nitrofurazone using cold 
homogenization technique. Results show type and percentage of surfactant, type of lipid 
and drug/lipid ration can influence SLN character and drug release from SLN was the 
rate limiting step for drug permeation across rat skin and so prepared formulations can act 
as a drug reservoir. 
25. Guangxi Zhai et al., investigated the development of penciclovir-loaded SLN and 
evaluate the potential of SLNs as the carrier of penciclovir for topical delivery. From the 
results it can be concluded that SLNs provide a good skin targeting effect and may be a 
promising carrier for topical delivery of penciclovir. 
26. Madhushudanan et al., developed arthemeter-loaded lipid nanoparticles and evaluated 
for mean particle size, zeta potential, encapsulation efficiency and histopathological 
analysis. Histopathological analysis showed no significant histological changes in liver 
and kidney tissues in mice treated with formulations. The results highlights the suitability 
of lipid nanoparticles to deliver parenterally the anti-malarial drug artemether. 
27. Yingchao Li et al., developed the SLN loaded traditional Chinese medicine by 
ultrasonication method. Stability evaluation showed relatively long-term stability with 
only slight particle growth (P > 0.05) after storage at room temperature for 4 weeks. 
Therefore, ultrasonication is demonstrated to be a simple, available and effective method 
to prepare high quality SLN loaded traditional Chinese medicine. 
28. Sanjay Garg et al., developed the lipid nanoparticles of chlorambucil. From the results, 
higher AUC values of formulation as compared to CLB solution (p < 0.01) in tumors 
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suggested that the presence of DDAB on the lipid nanoparticles resulted in greater 
accumulation of the drug in tumors. 
29. Vobalaboina Venkateswarlu et al., studied the SLN delivery systems of clozapine. 
Homogenization followed by ultrasonication method is suitable to produce SLN of 60–
380 nm size ranges. The results suggest that this system is most suitable for exploiting 
lymphatic transport pathway for improving oral bioavailability of clozapine. 
30. Vanna Sanna et al., investigated the effect of saturated fatty alcohols having different 
chain length (C12–C18), formulated into Precirol-based lipid nanoparticles, on the ex 
vivo skin permeability of Econazole nitrate. The analysis of results revealed that the 
effect of fatty alcohols on the Econazole nitrate permeation is structure-dependent, and 
associated with an increase of the permeability coefficients that can improve the 
interaction between alcohols and skin lipids. 
31. Marı´a J. Blanco-Prieto et al., developed a lipid nanoparticle system that would 
decrease systemic toxicity as well as to improve the therapeutic potential of the drug. It 
was concluded that compritol presents advantages as a matrix material for the 
manufacture of the nanoparticles and for the controlled release of edelfosine. 
32. Attama et al., described the characterization of SLN prepared using theobroma oil and 
fat as the main lipid matrix. And the results concluded that SLN of theobroma oil 
containing phospholipid could prove to be a good ocular or parenteral drug delivery 
system considering the low particle size, particle size stability and in vivo tolerability of 
the component lipids, which had higher increase in d90% on storage are suitable for 
preparation of topical and transdermal products. 
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33. Chun- ching lin et el., developed quercetin-loaded nanoparticles by a nanoprecipitation 
technique with eudragit and polyvinyl alcohol as carriers, and to evaluate the antioxidant 
effects of quercetin and of its nanoparticles. This system was characterized by particle 
size and morphology, yield and encapsulation efficiency, DSC, X-ray diffraction, FTIR, 
nuclear magnetic resonance and dissolution study. Particle size of < 85 nm, encapsulation 
efficiency over 99%, no interaction between the drug and lipid were obtained. The 
release of the drug from SLN was 74-fold higher compared with the pure drug. In 
addition, the antioxidant activity of quercetin was more effective than pure quercetin on 
DPPH scavenging, anti-superoxide formation, superoxide anion scavenging and anti-lipid 
peroxidation.  
34. Hu et al., developed clobetasol propionate by a novel diffusion method in aqueous system 
and physicochemical charactization were performed. The recovery lipophilic model drug 
clobetasol propionate was incorporated to study the recovery of nanoparticles, 
entrapment efficiency, zeta potential and drug delivery characterization. A novel 
preparation method and the optimized separation parameters in the present research for 
SLN were established. The results also demonstrate the principle suitability of SLN as a 
prolonged release formulation for lipophilic drugs. 
35. Shulka et al., studied the preparation and evaluation of polymethacrylic acid 
nanoparticles containing lamivuidine. The results suggested that the developed 
formulation overcome and alleviates the drawbacks and limitations of lamivudine 
sustained release formulations and could possibility be advantageous in terms of 
increased bioavailabilty of lamivudine. 
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36. Mandip singh et al., investigated the celecoxib-loaded SLN for pulmonary targeting. 
Celecoxib encapsulated SLN were found to be stable and aerodynamic properties were 
within the respirable limits. Aerosolization of celecoxib-SLN improved the celecoxib 
pulmonary bioavailability compared to solution formulation which will potentially lead to 
better patient compliance with minimal dosing intervals. 
37.  Vasheghani et al., developed ketoprofen-loaded SLN using beeswax and carnauba wax. 
The characteristics of the SLNs with various lipid and surfactant composition were 
investigated. It was found the SLN with more beeswax content in their core exhibited 
faster drug release as compared with those containing more carnauba wax in their 
structure. 
38. Souto et al., developed lopinavir SLN for intestinal lymphatic targeting. From the 
intestinal lymphatic transport study it became evident that SLN increased the cumulative 
percentage dose of lopinavir secreted into the lymph. The AUC for the lopinavir SLN 
was 2.13- fold higher than obtained for the conventional drug solution available in the 
market. From the results it was concluded that SLNs can be used both as a drug carrier 
for bioavailability enhancement and for targeting. 
39. Chong-kook et al., developed an alternative formulation of paclitaxel suitable for 
parenteral administration, paclitaxel-loaded sterically stabilized.  SLN were prepared, 
characterized  and examined for in vitro cytotoxicity. Treatment of the human ovarian 
cancer cell line and the breast cancer cell line with paclitaxel-loaded SLNs yielded 
cytotoxicities comparable to those of a commercially available Cremophor EL-based 
formulation. These results collectively suggest that our optimized SLN formulation may 
have a potential as alternative delivery system for pareteral administration of paclitaxe. 
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40. Jia-you fang et al., developed lipid nanoparticles as vehicles for topical psoralen 
delivery. Nanostructured lipid carriers (NLC) were also prepared for comparison. SLN 
and NLC showed respective mean particle sizes of 300 and 200 nm respectively. 
Hyperproliferative or psoralen-like skin produce by repeated strippings in the dorsal skin 
of mouse was also used as a permeation barrier. The results showed that the 
nanoparticulate systems could minimize the permeation differentiation between normal 
and hyperproliferative skin compared to the free drug in an aqueous control. 
41. Guihua huang et al., studied the preparation of temozolomide SLN, evaluation of its 
physiochemical characteristics, and to investigate the specific drug targeting of 
intravenous injected SLN of temozolomide. The results showed that the average diameter 
of 65.9 ± 11.8 nm with a zeta potential of -37.2 ± 3.6 mV and the release behavior was in 
accordance with higuchi – equation. In the tested organs, the AUC/dose and the MRT of 
SLN were much higher and longer than those of the drug solution. These results indicated 
that the SLNs is a promising sustained-release and drug-targeting system for antitumor 
drugs. 
42. Sami nazzal et al., studied the preparation and in vitro antiproliferative effect of 
tocotrienol loaded lipid nanoparticles (NLC) against noeplastic + SA mammary epithelial 
cells. Sonication time and pulsar rate were initially evaluated for their effect on the size 
and polydispersity of the nanoparticles using a full factorial design. Tocotrienol loaded 
lipid nanoparticles were shown to exhibit potent antiproliferative effect against neoplatic 
+ SA mammary epithelial cells. (NLC) had comparable IC50 as the reference drug 
solution, which signified the importance of  tocotrienol encapsulation within NLCs on 
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their activity. Furthermore, these findings suggested that NLCs may have potential value 
in the treatment of breast cancer. 
43. Vandana et al., investigated the development of tretinoin SLN and to evaluate the 
viability of an SLN based gel in improving topical delivery of tretinoin. The developed 
SLN were characterized for particle size, polydispersibility index, entrapment efficiency 
and morphology. Studies were carried out to evaluate in a significant improvement in the 
photostability in comparison to methanolic. In vitro permeation studies through rat skin 
indicated that an SLN based tretinoin gel has permeation profile comparable to that of the 
marketed tretinoin cream. 
44.  Yajiang yang et al., studied the characterization and release of triptolide-loaded poly ( 
D.L- lactic acid) nanoparticles prepared by modified spontaneous emulsification solvent 
diffusion method (SESD). From the evaluation studies, the morphology of the 
nanoparticles exhibited a fine spherical shape with smooth surfaces without aggregation 
or adhesion. The modified SESD method was a potential and advantage method to 
produce an ideal polymer nanoparticles for drug delivery system. 
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CHAPTER IV 
 
AIM OF WORK 
 
Asthma is a chronic inflammatory disease in which the patient has episodes of reversible 
airways obstruction due to bronchial hyperresponsiveness.  
 
 Montelukast sodium is a potent, selective and orally active leukotriene receptor 
antagonist that acts by inhibiting physiological actions of the cysteinyl leukotrienes. It is used in 
the prophylaxis and treatment of asthma exercise induced bronchospasm, allergic rhinitis, 
urticaria and to relieve symptoms of seasonal allergies.30,31 
 
Montelukast sodium is an orally active compound that binds with high affinity and 
selectivity to the CysLT1 receptor (in preference to other pharmacologically important airway 
receptors, such as the prostanoid, cholinergic or β-adrenergic receptor). Montelukast inhibits 
physiologic actions of LTD4 at the CysLT1 receptor without any agonist activity. 
 
The main drawback of conventional montelukast formulation is that it undergoes 
hepatic first pass metabolism. Thus, it shows plasma or biological half-life of 2.5 to 5.5 
hours, thereby decreasing bioavailability upto 64 %.  
. 
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Based on these considerations, solid lipid nanoparicles system was developed for the 
montelukast sodium (using various lipid such as stearic acid, glyceryl monostearate and 
compritol ATO 888) by hot homogenization followed by ultrasonication method) such delivery 
system will improve the biological half-life as well as bioavailabilty. In the proposed research 
work, montelukast sodium is formulated as SLN to improve the bioavailability by avoiding 
hepatic metabolism, greater therapeutic efficacy, and improve patient compliances. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
50 
 
CHAPTER V 
PLAN OF WORK 
 
PART-I 
1. Determination of λ max of montelukast sodium 
2. Calibration curve for montelukast sodium in 0.5 % sodiumlauryl sulphate solution 
 
PART-II 
Formulation of montelukast sodium loaded solid lipid nanoparticles using different 
concentrations of lipids (glyceryl behenate, glyceryl monostearate and stearic acid) by hot 
homogenization followed by ultrasonication. 
 
PART-III 
Evaluation of montelukast sodium loaded solid lipid nanoparticles  
1. Determination of drug content of SLN formulations 
2. Determination of entrapment efficiency 
3. In –vitro release studies of SLN dispersion  
4. Estimation of release kinetics 
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PART-IV 
5. Measurement of particle size of SLN formulations 
6. Morphological studies of SLN dispersion using scanning electron microscopy 
 
 
PART-V 
7. Stability studies of SLN dispersion at refrigerated and room temperature. 
 
PART-VI 
8. Differential scanning calorimetry studies of drug with lipid was conducted to determine  
the compatibility of drug with lipid.  
9. IR studies to determine interaction between lipids and drug. 
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CHAPTER-VI 
MATERIALS AND EQUIPMENTS 
 
 
MATERIALS USED 
 
1. Drug- Montelukast Sodium    - Microlabs, Hosur 
 
2. Glyceryl monostearate    - Central drug house 
 
3. Glyceryl behenate     - Orchid Pharma 
 
4. Stearic acid                     - Universal Scientific  
 
5. Polyvinyl alcohol     - Sisco research lab 
 
6. Sodiumlauryl sulphate                        - Loba chemie 
 
7. Dichloromethane     - Rankem 
 
8. Methanol      - Rankem 
                                                                                        
9. Ethanol                         - Central drug house                    
                                                                                       
10. Dialysis membrane 50 – LA 387   - Himedia 
 
 
 
 
 
    
53 
 
EQUIPMENTS USED 
 
 
1. Rotary Flash Evaporator   - Super fit rotary flash evaporator  
2. Ultra Sonicator   - Vibronic’s Ultrasonic processor 
3. Centrifugator                                       - Eppendorf Centrifuge 5417 R 
4. Mechanical stirrer   -  Scientific industries  
5. Electronic Balance   - A&D Company, Japan 
6. Magnetic Stirrer   - MC Dalal & co  
7. UV Visible Spectrophotometer - UV Pharma Spec 1700, Shimadzu 
8. Refrigerator    - Kelvinator  
9. Stability chamber                            - Inlab equipments. 
 
 
 
 
 
 
 
 
    
54 
 
CHAPTER VII 
 
MONTELUKAST SODIUM 
 
DRUG PROFILE 
  
 
 Montelukast sodium is a potent, selective and orally active leukotriene receptor 
antagonist that acts by inhibiting physiological actions of the cysteinyl leukotrienes. It is used in 
the prophylaxis and treatment of asthma exercise induced bronchospasm, allergic rhinitis, 
urticaria and to relieve symptoms of seasonal allergies.30,31 
 
STRUCTURAL FORMULA:31,32 
                  
 
EMPIRICAL FORMULA:32,33,34 
C35H35ClNNaO3S5  
CHEMICAL NAME:1,30,32 
[R-(E)]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-
methylethyl)phenyl]propyl]thio]methyl acid] cyclopropaneacetic monosodium salt. 
    
55 
 
 
DESCRIPTION:1,30,31,32 
Nature                  :  White to off-white powder. 
Solubility             :   Freely soluble in ethanol, methanol and water, and  
                                practically  insoluble in acetonitrile. 
    Melting point       :  135.5°C 
Molecular weight :  608.2 
 
MECHANISM OF ACTION: 34,35,36  
The cysteinyl leukotrienes { LTC4, LTD4, LTE4} are products of arachidonic  acid 
metabolism and are released from various cells, including mast cells and eosinophils. These 
eicosanoids bind to cysteinyl leukotriene receptors ( CysLT) found in the human airway. 
Cysteinyl leukotrienes and leukotriene receptor occupation have been correlated with the 
pathophysiology of asthma, including airway edema, smooth muscle contraction and altered 
cellular activity associated with the inflammatory process, which contribute to the signs and 
symptoms of asthma.  
Montelukast sodium is an orally active compound that binds with high affinity and 
selectivity to the CysLT1 receptor (in preference to other pharmacologically important airway 
receptors, such as the prostanoid, cholinergic or β-adrenergic receptor). Montelukast inhibits 
physiologic actions of LTD4 at the CysLT1 receptor without any agonist activity. 
PHARMACOKINETICS: 31,32,33,34,35,36 
Absorption:  
 It is rapidly absorbed after oral administration 
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 Cmax is achieved in 2 hours 
Tmax is achieved  in 3 to 4 hours. 
 Mean oral bioavailability is 64 % 
Distribution:  
99 % bound to plasma proteins 
 Steady state volume of distribution is 8 to 11 litres 
Metabolism:  
 Extensively metabolized by liver 
 Cytochrome P450 3A4 and 2C9 are involved in the metabolism of montelukast 
Elimination: 
 The plasma clearance of montelukast averages 45 ml/min  
 Mean plasma half-life is 2.7 to 5.5 hours 
 Montelukast and its metabolites are excreted almost exclusively via the bile 
Therapeutic indicatons: 
Leukotriene receptor antagonist 
Chronic asthma 
        Allergic rhinitis 
         Prophylaxis for exercise-induced asthma 
  Acute asthma attack 
 
Dose 
 4 – 10 mg per day 
 
Side effects 
 Oedema 
 Agitation 
 Restlessness 
 Allergy 
 Chest pain 
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 Tremor 
 Dry mouth 
 Vertigo 
 Arthralgia 
 Sedation 
 Palpitations 
 Suicidality 
 Anxiousness 
 
Drug interactions:  
 Phenobarbital which induces hepatic metabolism and decreased the AUC 
  
Precautions: 
Not indicated for use  in the reversal of bronchospasm in acute asthma attack. 
Should not be abruptly substituted for inhaled or oral corticosteroids 
Should not be used as monotherapy for the treatment and management of exercise 
induced bronchospasm 
Pateints with aspirin sensitivity should discontinue aspirin or other NSAIDs 
Churg-Strauss syndrome 
 
Contra-indications: 
 Hypersensitivity to any component of this product 
 
Brand names: 24 
 Admont 
 Emlukast 
 Kast 
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 Molly 
 Montal 
 Montasma 
 Montelast 
 Monti 
 Reokast 
 Romilast 
 Telecast 
 
 
 
 
 
 
 
 
 
 
  
GLYCERYL MONOSTEARATE
SYNONYM:1,2,3,4,81 
           Glyceryl stearate,  Monostearin
STRUCTURE: 
 
CHEMICAL NAME: 1,2,3,4,8
 3-Stearoyloxy-1,2-propanediol; Glyceryl 
Octadecanoic acid, 2,3-dihydroxypropyl ester; Glycerin 1
Glycerol alpha-monostearate; Glyceryl 1
Stearic acid 1-monoglyceride; 1-
1,2,3-Propanetriol 1-octadecanoyl ester.
 
CHAPTER VIII                                      
 EXCIPIENTS PROFILE                             
 
 
 
1 
stearate; Alpha-Monostearin; Monostearin; 
-monostearate; Glycerin 1
-monostearate; Stearic acid alpha-monoglyceride; 
Glyceryl stearate; 1-Monostearin; 1-Monostearoylglycerol; 
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-stearate; 
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EMPIRICAL FORMULA: 
          CH3 (CH2)16COOCH2CHOHCH2OH 
MOLECULAR WEIGHT: 
 358.56 
FUNCTIONAL CATEGORY:81 
          Emulsifying agent 
DESCRIPTION : 
          White or cream colored waxy solid. 
PROPERTIES : 1,2,3,4,81 
          Physical state  : white powder 
          Melting point  : 63 - 68 oC  
          Boiling point  : > 100 oC 
          Solubility in water : soluble in hot water 
          Solvent solubility : soluble in methanol and chloroform mixture 
          HLB value  : 5.0 
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STABILITY AND STORAGE CONDITIONS: 
          It is stable under ordinary conditions, and should be stored in a well-closed container and 
protected from light. 
SAFETY: 
          It is generally regarded as an essentially non-toxic and non-irritant material at the levels 
employed as an excipients. 
HANDLING PRECAUTIONS:81 
          Keep away from heat. Keep away from sources of ignition. Empty containers pose a fire 
risk, evaporate the residue under a fume hood. Ground all equipment containing material. Do not 
breathe dust. 
REGULATORY STATUS : 
          Included in the FDA inactive ingredients. Recognized  by GRAS status. 
 
                                        GLYCERYL BEHENATE 
SYNONYMS: 1,2,3,4,81 
          Compritol 888 ATO; 2,3-dihydroxypropyl docosanoate; docosanoic acid, glyceryl 
monobehenate, 1,2,3-Propanetriol docosanoate. 
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STRUCTURE: 
                       
EMPIRICAL FORMULA: 
                 C3H8O3.x(C22H44O2) 
MOLECULAR WEIGHT: 
                 414.66 
FUNCTIONAL CATEGORY: 
        Coating agent 
        Tablet binder 
        Tablet and capsule lubricant 
 
DESCRIPTION: 
        Fine white powder or hard waxy mass with a faint odor. 
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PROPERTIES: 1,2,3,4,81 
          Physical state          :          Fine white powder  
          Melting point          :          65–77ºC 
          Boiling point           :         306 ºC 
          Solubility                 :          Soluble, when heated, in chloroform and dichloromethane,  
                                                      practically insoluble in ethanol (95%), hexane, mineral oil, and            
                                                     water. 
          HLB value               :         12 
STABILITY AND STORAGE CONDITIONS : 
          It should be stored in a tight container, at a temperature less than 358C. 
SAFETY : 
          It is generally regarded as a relatively nonirritant and nontoxic material. 
HANDLING PRECAUTIONS : 
          It emits acrid smoke and irritating fumes when heated to decomposition. 
REGULATORY STATUS : 
          Included in the FDA Inactive Ingredients Guide (capsules and tablets).                                                         
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                                            STEARIC ACID 
SYNONYMS: 1,2,3,4,81 
          Cetylacetic acid; stereophonic acid; Tegostearic. 
STRUCTURE: 
           
CHEMICAL NAME: 
          Octadecanoic acid  
EMPIRICAL FORMULA: 
          C18H36O2 
MOLECULAR WEIGHT: 
          284.47 
FUNCTIONAL CATEGORY: 1,2,3,4,81 
         Emulsifying agent  
         Solubilizing agent 
         Tablet and capsule lubricant 
    
65 
 
DESCRIPTION: 
          It is a hard, white or faintly yellow-colored, crystalline solid or a white or yellowish white 
powder.  
PROPERTIES: 1,2,3,4,81 
          Physical state          :     Crystalline solid/white or yellowish powder. 
          Melting point          :          554°C 
          Boiling point           :         383°C 
          Solubility                :          Freely soluble in benzene, carbon tetrachloride, 
                                                     chloroform, and ether; soluble in ethanol (95%), hexane, 
                                                     and propylene glycol; practically insoluble in water. 
 HLB value            :          15 
 
STABILITY AND STORAGE CONDITIONS:81 
          It is a stable material; an antioxidant may also be added to it. The bulk material should be  
stored in a well-closed container in a cool, dry place. 
SAFETY : 
          It is generally regarded as a nontoxic and nonirritant material. However, consumption of  
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excessive amounts may be harmful. 
HANDLING PRECAUTIONS : 
          Stearic acid dust may be irritant to the skin, eyes, and mucous membranes. Eye 
protection, gloves, and a dust respirator are recommended. Stearic acid is combustible. 
REGULATORY STATUS : 
          Included in the FDA Inactive Ingredients Guide (sublingual tablets; oral capsules,  
solutions, suspensions, and tablets; topical and vaginal preparations).  
                                                  
                                       POLYVINYL ALCOHOL 
SYNONYMS: 1,2,3,4,81 
          Airvol; Gelvatol; Polyvinol. 
STRUCTURE: 
           
CHEMICAL NAME: 
          Ethenol, homopolymer  
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EMPIRICAL FORMULA:  
          (C2H4O)n  
MOLECULAR WEIGHT: 
          20,000 – 200,000  
FUNCTIONAL CATEGORY: 1,2,3,4,81 
          Coating agent 
           Lubricant 
           Stabilizing agent 
           Viscosity-increasing agent 
DESCRIPTION: 
           Odorless, white to cream-colored granular powder. 
PROPERTIES:4,81 
          Physical state          :          White powder 
          Melting point          :          180–190°C  
          Boiling point           :         228 °C  
          Solubility                :          Soluble in water; slightly soluble in ethanol (95%); insoluble in                            
                                                    organic solvents.  
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        HLB value              :         10 - 15 
STABILITY AND STORAGE CONDITIONS:81 
          It is stable when stored in a tightly sealed container in a cool, dry place. It is stable on  
exposure to light. 
SAFETY 
          It is generally considered a nontoxic material. It is nonirritant to the skin and eyes at  
concentrations up to 10%; concentrations up to 7% are used in cosmetics. 
HANDLING PRECAUTIONS 
          Eye protection and gloves are recommended. Polyvinyl alcohol dust may be an irritant on 
inhalation. Handle in a well-ventilated environment. 
REGULATORY STATUS 
          Included in the FDA Inactive Ingredients Guide (ophthalmic preparations and oral tablets).  
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CHAPTER IX 
EXPERIMENTAL PROTOCOL 
 
 PREPARATION OF CALIBRATION MEDIUM:  
0.5 % SODIUM LAURYL SULPHATE SOLUTION: 
Weigh 5 grams of sodium lauryl sulphate and dissolve it in specified amount of distilled 
water with continuous stirring and this solution is make up to 1000 ml using distilled water to 
prepare 0.5 % Sodium lauryl sulphate. 
 
PREPARATION OF CALIBRATION CURVE FOR MOTELUKAST SODIUM:25,26,27,28 
The standard stock solution of Montelukast sodium is prepared by dissolving 100 mg of 
drug in 5 ml ethanol and diluted with 0.5 % SLS solution up to 100 ml. From the above stock 
solution, drug having different concentration of 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10µg /ml 
concentration is prepared in using 0.5 % SLS solution with appropriate dilution. 
The 10 ug/ml solution is scanned in UV spectrophotometer to find the λmax and the 
absorbance of the samples is measured at λmax (345nm). A graph is plotted by taking 
concentration in X-axis and absorbance in Y-axis to obtain the standard curve. 
The standard curve prepared is used to estimate drug content, entrapment efficiency and 
percentage drug release. 
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FORMULATION OF MONTELUKAST SODIUM LOADED SOLID LIPID 
NANOPARTICLES: 
Solid lipid nanoparticles are prepared by a Hot homogenization followed by 
Ultrasonication method. Montelukast sodium loaded solid lipid nanoparticles is prepared by 
using three different type of lipids (Compritol ATO 888, Glyceryl- monostearate  and Stearic 
acid) of various concentrations of lipid i.e.1, 2, 5, 10, 15 and 20 %. Drug(10 mg) and Surfactant 
(100 mg) concentration is kept constant for all the formulations.  Surfactant, Polyvinyl alcohol is 
used as a stabilizer to enhance the solubility of the drug in the lipid. 
PROCEDURE:37,38,42,46,49,56 
Montelukast sodium loaded SLN is prepared by a hot homogenization followed by 
ultrasonication method. Montelukast sodium and lipid of various concentration of lipid i.e.1, 2, 
5, 10, 15 and 20 % is weighed and dissolved in ethanol. Organic solvents are completely 
removed using a rotary flash evaporator. The embedded lipid layer was melted by heating 5-
10°C above the melting point of the lipid. An aqueous phase is prepared by dissolving polyvinyl 
alcohol (1% W/V) in distilled water (sufficient to produce 30 ml of preparation) and heating to 
the same temperature as oil phase. The hot aqueous phase is added to the oil phase and 
homogenization is performed (at 2000 rpm) using a mechanical stirrer for 60 minutes. The 
obtained coarse emulsion is allowed to cool to room temperature and stirred at 400 rpm for 30 
mins. Then it is ultrasonicated using a vibronic’s ultrasonic processor for 10 minutes. 
Montelukast sodium loaded SLN is finally stored in amber coloured containers. 
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CHARACTERISATION OF MONTELUKAST SODIUM LOADED SLN: 
The formulated Montelukast sodium loaded solid lipid nanoparticles are evaluated for its 
drug content, entrapment efficiency, Particle size, SEM studies, DSC studies, FTIR studies and 
in vitro drug release studies. 
PHYSICOCHEMICAL PROPERTIES:40,42 
 The SLN dispersions were characterized for physicochemical properties such as color, 
odor and stability after centrifugation. Centrifugation was performed at 2000 rpm for 30 minutes. 
DETERMINATION OF DRUG CONTENT:37,42 
1 mg equivalent of SLN dispersion is dissolved in 1 ml of ethanol and the volume is 
made upto 100 ml to make 10 ug / ml concentration and the absorbance is measured at 345 nm. 
From the absorbance drug content is measured. 
DETERMINATION OF ENTRAPMENT EFFICIENCY:37,41,44  
Entrapment efficiency of Montelukast sodium loaded SLN is determined by 
Centrifugation method. The nanoparticles are separated in a high speed cooling centrifuge at 
14,000 rpm for 90 minutes at 4oC. The sediment and supernatant liquid are separated. The 
supernatant solution is made up to desired volume with buffer. The amount of drug that is not 
incorporated in the SLNs could be obtained by the UV –spectrophotometer. The absorbance of 
the samples is measured at 345 nm to estimate the percentage entrapment efficiency. 
 The entrapment efficiency is calculated by following formula: 
                      Amount taken – Free drug   
% Entrapment efficiency=                                               × 100. 
                                                   Amount taken 
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PARTICLE SIZE ANALYSIS:47,51 
The mean diameter of SLNs in the dispersion was determined by photon correlation 
spectroscopy (PCS) using a laser light scattering instrument (LS230; COULTER)  at  a fixed 
angle of 90° at 25 °C. The particle size analysis data was evaluated using the volume 
distribution. Before measurement 1 ml of sample is diluted with distilled water. 
IN VITRO DRUG RELEASE:37,45 
In vitro release of Montelukast sodium from Montelukast sodium-loaded SLN 
formulations was determined by dialysis bag method using 0.5 % Sodium lauryl- sulphate 
solution as dissolution medium. Dialysis membrane having pore size 2.4 nm, molecular weight 
cut off 14,000 was used. Membrane was soaked in distilled water for 15 mins before using. 1 mg 
equivalent of drug in SLN dispersion was placed in the dialysis bag and kept in a beaker 
containing 250 ml of 0.5 % SLS solution as buffer.  The dissolution medium was continuously 
stirred at 100 rpm and maintained at 37°C ± 2°C. Samples were withdrawn at predetermined 
time intervals, and the volume withdrawn was replaced with same volume of fresh dissolution 
medium.  Samples were analyzed for Montelukast sodium drug content spectrophotometrically 
by measuring the absorbance at 345 nm against a suitable solvent blank. All experiments were 
repeated triplicate, and the average values were taken. 
KINETIC MODELING:69,70 
In order to understand the kinetic and mechanism of drug release, the  result of  in vitro 
drug release study of nanoparticles were fitted with various  kinetic equation  like zero order 
(cumulative % release vs. time), first order  (log % drug remaining vs time), Higuchi’s model 
(cumulative %  drug release vs. square root of time). r2 and k values were calculated for the 
    
73 
 
linear curve obtained by regression analysis of the above plots. The exact mechanism by which 
the SLN formulations follows is determined by korse-meyer peppas model (log drug release vs 
log time). 
SCANNING ELECTRON MICROSCOPY:45,54,61  
 Average particle size and surface morphology of the best formulation are evaluated using 
scanning electron microscopy. The sample was spread on an aluminium stub and allowed to dry 
at room temperature. The dried sample then was sputter coated with gold for 40 seconds using 
Hitachi Ion-Sputter E-1010. The images were captured with the Hitachi S-3400 Scanning 
Electron Microscope. 
FT-IR STUDIES:41,45,55 
 The interaction between the drug with lipids is studied by using IR 
Spectrophotometer. Drug, lipid and its physical mixtures were subjected to FTIR studies. The 
FT-IR spectrum of pure drug and combination of drug with excipient are obtained by using 
Shimadzu FT-IR Spectrophotometer. The scanning range is 450-4000 cm-1 and the resolution is 
4cm-1. Samples are prepared in KBr pellets. 
DIFFERENTIAL SCANNING CALORIMETRY:41,45,53 
 Differential Scanning Calorimetry is performed using Perkin Elmer STA 6000 Thermal 
Analyzer. The instrument is calibrated with indium standard. Accurately weighed (it varies from 
3mg-25mg) samples are placed in an open type ceramic sample pans. Thermo grams are 
obtained by heating the sample at a constant heating rate of 8ºC/minute. A dry purge of Argon 
gas (60ml/min) is used for all runs. Samples heated from 37ºC-400ºC. DSC thermograms were 
recorded for montelukast sodium pure drug, stearic acid, glyceryl monostearate, compritol ATO 
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888 and its physical mixture. For the investigation investigation of bulk material, about 1-2 mg 
of sample was used.  
STABILITY STUDIES:45,54,61 
 According to modified ICH guidelines, all formulations of Montelukast sodium-loaded 
SLN were subjected to stability studies at 25±20 C and 60 ± 5 RH for 1 month also at 40C and 
the entrapment efficiency is estimated for all the formulations at 1 week time intervals for 1 
month. 
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CHAPTER X 
                                      RESULTS AND DISCUSSION 
DETERMINATION OF λ – MAX OF MONTELUKAST SODIUM: 
 The λ max of montelukast sodium was estimated by scanning the 10µg/ml concentration 
of the drug solution in UV region (200-400 nm). It showed the λ max of 345nm. The absorption 
spectra are shown in the fig. 11. 
CALIBRATION CURVE OF MONTELUKAST SODIUM:  
 The calibration curve of montelukast sodium was prepared by using distilled water and 
0.5 % SLS solution. Linear correlation coefficient was obtained for calibration of montelukast 
sodium in each medium. Montelukast sodium obeyed the Beer’s law. Linearity was observed in 
the concentrations of 5 to 50 µg/ml.  Calibration plot of montelukast sodium was shown in fig. 
12 and the values in table 2. 
DRUG CONTENT: 
 The drug content of all the formulations varied from 94.75 to 100 % and are shown in the 
table 3. 
 PREPARATION OF MONTELUKAST SODIUM LOADED SLN: 
 Homogenization followed by ultrasonication is a reliable, simple and reproducible 
method for preparing SLN. The composition of the formulations are shown in table 1. The 
prepared SLN dispersion was found to be uniform and homogenous in appearance.  
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PHYSICOCHEMICAL PROPERTIES: 
            The SLN dispersion was white in color, odorless, and fluid in nature. It was stable and 
did not show sedimentation even after centrifugation (2000 rpm for 30 minutes).     
ENTRAPMENT EFFICIENCY: 
 The results of EE were shown in the table 4 and 5 and fig. 13. The influence of surfactant 
and lipid concentration is discussed below: 
Influence of surfactant on entrapment efficiency: 
 Incorporation of 1 % polyvinyl alcohol, to stearic acid containing formulations               
(F 1 – F 6) showed  EE of 23.1 – 29.3 %, to glyceryl monostearate containing  formulations (F 7- 
F 12) showed EE of 21.7  –  42.6 % and to compritol ATO 888 containing formulations (F 13- F 
18)  had EE of 42.6 – 62.3 % (F 13 – F 18) shown in table 4. By Incorporating 2 % polyvinyl 
alcohol the EE was found to be 42.4 – 88.1 %, 40.5 – 79.3 % and 81.4 – 92.6 % respectively. 
From the results, it was found that an increase in surfactant concentration increases EE33 
independent of type and concentration of lipids. 
Influence of lipid material on entrapment efficiency: 
 The EE of the formulations containing stearic acid (F 1- F 6) ranging from 42-88 %, 
glyceryl monostearate (F 7- F 12) ranging from 40.5- 79.3 % and compritol ATO 888 (F 13- F 
18) 81.4 - 92.3 %. The results indicated that, increasing the lipid concentration also increases 
the EE.  This may be due to the reason that higher concentration of lipid would provide more 
    
77 
 
space to increment of the lipid content and also reduces the escaping of drug into the external 
phase thus ensuring highest EE47, 61, 63,64.   
The EE of the three lipids was in the order of  
   COMPRITOL > GLYCERYL MONOSTEARATE > STEARIC ACID.  
Among the 3 lipids used, compritol showed the highest EE when compared to glyceryl 
monostearate and stearic acid. This may be due to the fact, that the presence of long chain fatty 
alcohol could lead to the creation of a less ordered solid lipid matrix and leaves enough space to 
accommodate drug molecules47, 61, 66, 79. (Compritol molecular formula (MF): C25H52O6, glyceryl 
monostearate MF: C21H42O4 and stearic acid MF: C18H36O2). 
PARTICLE SIZE ANALYSIS: 
 The particle size analysis of the SLN formulations was estimated by dynamic light 
scattering technique. The particle size values are shown in table 6 and the distribution curves 
were shown in fig. 14-21. 
Influence of surfactant concentration on particle size: 
 To optimize the surfactant concentration in order to obtain the SLN formulation in the 
nano-range, two concentrations of surfactant in empty SLNs were examined for mean particle 
size.  
Empty SLN containing 1 % polyvinyl alcohol showed the mean particle size of 10.24 µm 
and when the concentration of polyvinyl alcohol was increased to 2 %, the SLN formulation 
showed the mean particle size of 50 nm. This may be due to the reason that at low surfactant 
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concentration, an optimal surface coverage of the surfaces may not be achieved resulting in less 
than optimal stabilization of the particle dispersion. Under these circumstances it would be 
expected that the particles would tend to aggregate50. Decreased particle size with increase in 
mobile surfactant concentration may be due to the combined effect of decreased interfacial 
tension and increased rate of particle disintegration during homogenization63, 68.  
These results suggested that relatively high surfactant concentration were needed to 
prevent particle aggregation46, 47, 50. Hence 2 % polyvinyl alcohol was optimized to get the 
SLN in the nano – size range. 
Influence of lipid concentration on particle size: 
 5 % stearic acid   containing formulation showed the mean particle size of 50 nm while 
20 % stearic acid containing formulation showed the mean particle size of 2.30 µm. Glyceryl -
monostearate containing formulations at 5% showed the mean particle size of 53 nm and at 20% 
concentration had 2.45 µm. For compritol containing formulations mean particle size was 80 nm 
and 2.60 µm for 5% and 20% respectively. 
. From the results, it was noted that the drug: lipid ratio was found to have a positive effect 
on particle size i.e. increase in lipid concentration resulted in larger mean particle sizes and 
broader size distributions4. This was because of increased viscosity of inner phase that affected 
the shearing capacity of homogenizer.41, 45, 46, 63 
Larger particle size with increase in lipid content could be attributed to decrease in 
emulsifying efficiency and increase in particle agglomeration53. 
The decreasing order of particle size for the three lipids is as follows: 
    
79 
 
 Compritol < Glyceryl monostearate < Stearic acid. 
 Of the three lipids used stearic acid containing formulations showed lesser mean particle 
size than the glyceryl monostearate and compritol. This may be due to the tendency of  SLN to 
increase in size with the increase in carbon chain length of the lipids and higher melting point 
lipid37 (Compritol melting point, MP: 55°C, glyceryl monostearate MP: 60°C, and stearic acid 
MP: 72°C ). 
 From the results, 5 % concentration of all three lipids was optimized to get an SLN 
formulation in nanometric size range.  
IN VITRO RELEASE STUDIES: 
  SLN containing three different lipids displayed a similar biphasic drug release pattern 
with a burst release within 30 minutes followed sustained release afterwards. The reason for 
burst release is possibly due to the drug associated with the surface of nanoparticles. The values 
are shown in table 7,8,9 and 10 and graphs in fig. 22-27.   
Initial burst effect: 
The initial burst effect of the formulations containing stearic acid varied from 7.5-21.9 % 
(F 1- F 6); GMS were 9-15.4 (F 7- F12) and compritol 9.3-16.3 (F 13- F 18). From the results, it 
was concluded that higher lipid ratio leads to higher initial burst release54. 
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Sustained effect: 
  After the burst release, SLN formulations showed sustained release. The release of drug 
from the formulations varied from 56.0-29.1 (F 1- F 18). Of all the formulations F 18 showed 
much slower release than the other formulations.    
 From the results, it showed that the release was chiefly dependent on the concentration of 
the lipids i.e. increase in lipid concentration decreases release rate66. 
 Among the three lipids used, compritol showed more sustained release than the stearic 
acid and glyceryl monostearate due to its longer carbon chain length than the other two lipids. 1, 5, 
6,9,20.
 
 The order of drug release from the three lipids as follows: 
 Compritol > Glyceryl monostearate > Stearic acid.  
From the results it was concluded that higher lipid concentration decreases release rate35. The 
nature of fatty acids affected the release significantly and longer the carbon chain length of fatty 
acids, the slower the drug release37, 41,42,45,56  
Comparison of In vitro drug release of  montelukast sodium loaded SLN with montelukast 
sodium pure drug solution : 
 The release of montelukast sodium from all the formulations was varied from 59.1-29.1 
at 12 hours whereas the release of montelukast sodium from pure drug solution was found to be 
99.1 % at 4 hours. This confirmed that the release of drug from all SLN formulations was more 
    
81 
 
sustained than the montelukast sodium pure drug solution (1mg/ml) shown in fig 28 (pure drug 
with best formulation) and fig. 29. 
RELEASE KINETICS: 
The kinetics and mechanism of drug release were studied by  release kinetics, the n, k and 
r2 values are indicated in the table 11. All the formulations showed first-order  release  which had 
higher linearity than the zero-order or higuchi model.  
The exact mechanism of the release kinetics was determined by korsemeyer peppas 
model.Results indicated that all the SLN formulations followed non-fickian model of release 
kinetics. 
 The kinetic modeling of the best formulation is shown in fig. 30. 
SCANNING ELECTRON MICROSCOPY (SEM) STUDIES: 
 The morphology of montelukast sodium – loaded SLN dispersion was examined by 
scanning electron microscope. The best formulation, F 15 (formulation containing 5 % 
compritol) was chosen for SEM studies. The SEM photograph was shown in the fig. 31.  It 
revealed that the SLN dispersion showed the particle size was found to be less than 500 nm in 
size with spherical shape and almost smooth surface.  
FT - IR STUDIES:  
FT-IR studies were carried out to confirm the compatibility between the drug 
(Montelukast sodium) and lipids used (stearic acid, glyceryl monostearate and compritol) FTIR 
spectra for pure drug, lipids used and its physical mixture were evaluated. The FTIR spectra are 
shown in fig. 32-38.  
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Montelukast sodium pure drug shows the bond vibrations at 3396 cm-1 (COOH 
stretching), 3057 cm-1 (aromatic C–H stretching), 2925 cm-1 (aliphatic C–H stretching), 1710 cm-
1
 (C- Ostretching), 1610 cm-1 (C C stretching), 1594 cm-1 (C N stretching), 1497 cm-1 (aliphatic 
C–H bending), 1132 cm-1 (C–O stretching), 1068 cm-1 (aromatic C–Cl stretching), 837 cm-1 
(aromatic C–H bending) and 697  (C–S stretching) (shown in table 12). 
 FTIR spectrum of stearic acid shows absorption bands of  C – H stretching at 2957 cm-1, 
C – H bending at 1465 cm-1, O – H bending at 1433 cm-1 and C – C stetching at 1099 cm-1,  
glyceryl monostearate  revealed absorption bands of C – H stretching at 3015 cm-1, C – H 
bending at 1735 cm-1 and O – H bending at 1290 cm-1 and compritol shows the absorption bands 
of C – H stretching at 2815 cm-1 and 2849 cm-1 and C = O stretching at 1738 cm-1 (mentioned in 
table 12). 
 From the physical mixtures of drug and lipids, there are no major shifting as well as no 
loss of functional peaks between the spectra of drug, lipids and its physical mixtures. Hence, it 
was confirmed that there is no interaction between the drug and lipids used. 
DSC STUDIES: 
 DSC is a highly useful means of detecting drug – excipient incompatibility. DSC 
thermograms of pure drug (montelukast sodium), lipids (stearic acid, glyceryl monostearate and 
compritol) and the physical mixtures of drug with lipids used were studied. 
 The drug showed the sharp melting endothermic peak at 125 °C, stearic acid showed the 
melting endothermic peak at 57 °C, glyceryl monostearate at 55 °C and compritol at 60 °C. The 
endothermic peak of  physical mixtures are drug and stearic acid  at 53 °C and 126 °C, drug and 
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glyceryl monostearate at 57°C and 125 °C and drug and compritol at 60 °C and 125 °C (shown 
in table 13 and fig. 39-45. 
 However, there was no obvious change in the endothermic peak around 125 °C of the raw 
material in physical mixtures. This suggested that there were no appearance of new peaks or 
disappearance of existing peak. Hence there was no considerable effect on the thermal 
behavior of drug with the lipid matrix under the experimental conditions. 
STABILITY STUDIES OF MONTELUKAST SODIUM- LOADED SLN  
 2 sets of SLN formulations were examined for stability studies. One set were 
stored at refrigeration temperature ( 4 ± 2°C ) and the other set were stored at 25 ± 2 °C and 60 
%  ± 5 %RH  at the stability chamber for 1 month and the entrapment efficiency were 
determined at 1 week intervals. 
 After 1 month of the stability studies, the entrapment efficiency of all the 
formulations which decreased from  42.40 – 92.60 % to 41.50 – 90.30 % at 4°C and 40.10 – 
89.50 %  at 25 ± 2 °C. The results are shown in table 14 and 15.  
From the results, lowered entrapment efficiency were observed on storage, this may be 
due to drug expulsion during lipid modification13, 25, 29.  
Hence it was concluded that at 4°C and 25 °C the formulations showed no significant 
change in entrapment efficiency54. 
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CHAPTER XI                                                   
SUMMARY AND CONCLUSION 
 The present research study was to estimate the effect of lipids on the 
preparation of montelukast sodium-loaded SLN to improve its bioavailability 
and to attain sustained release. 
 Result suggests that the hot homogenization and ultrasonication method was a 
feasible method for preparing Montelukast sodium- loaded fatty acid SLN. 
 SLN formulations were estimated for its particle size, morphology, 
entrapment efficiency, release studies, FTIR , DSC and stability studies. 
 From the particle size studies, it was observed that increase in surfactant 
concentration from 1 to 2 % decreases the mean particle size of the 
formulation. 
 SEM studies revealed that the SLN formulation are in the nanometric range 
and are spherical in shape with smooth surface. 
 The entrapment efficiency were found to increase with increase in surfactant 
concentration and with increase in lipid concentration. 
 The results obtained from the release studies revealed that all the SLN 
formulations have sustained release than the pure drug solution. 
 The release of montelukast sodium from the SLN formulation follows first 
order model of release kinetics. 
 From the FTIR and DSC studies, it was confirmed that there is no interaction 
between the drug and lipids used. 
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 From the stability studies it was noted that, there is a no considerable decrease 
in the entrapment efficiency of the SLN formulations. 
CONCLUSION: 
Finally, it was concluded that hot homogenization followed by ultrasonication is a 
feasible method. Particle sizes of SLNs revealed that the SLN prepared from higher melting 
point lipid showed larger particle size and with increased carbon chain length of the fatty acids. 
FTIR and DSC studies suggested that there is no interaction between drug and lipids. Studies 
showed that, increase in lipid concentration increased particle size, EE, and maintained the 
sustained release of drug.  Among all, Compritol ATO 888 is chosen as the best lipid for 
formulating SLN because it had higher EE and sustained drug release profile than GMS and 
stearic acid. It was concluded that the SLN provide sustained release and are preferred to 
overcome oral bioavailability problems and suggests that montelukast sodium can formulate as 
SLN system. 
 
 
TABLE 1 
 
 
COMPOSITION OF SLN FORMULATIONS 
 
 
 
 
S.NO 
 
 
FORMULATIONS 
 
SURFACTANT 
CONC. 
 
LIPID 
 
 
CONC. 
1 F 1 2 % STEARIC ACID 1  % 
2 F 2 2 % STEARIC ACID 2  % 
3 F 3 2 % STEARIC ACID 5  % 
4 F 4 2 % STEARIC ACID 10 % 
5 F 5 2 % STEARIC ACID 15 % 
6 F 6 2 % STEARIC ACID 20 % 
7 F 7 2 % GMS 1  % 
8 F 8 2 % GMS 2  % 
9 F 9 2 % GMS 5  % 
10 F 10 2 % GMS 10 % 
11 F 11 2 % GMS 15 % 
12 F 12 2 % GMS 20 % 
13 F 13 2 % COMPRITOL 1  % 
14 F 14 2 % COMPRITOL 2  % 
15 F 15 2 % COMPRITOL 5  % 
16 F 16 2 % COMPRITOL 10 % 
17 F 17 2 % COMPRITOL 15 % 
18 F 18 2 % COMPRITOL 20 % 
 
 
 
 
 
 
     
 
 
 
TABLE 2 
 
CALIBRATION OF MONTELUKAST SODIUM IN 0.5 % SLS 
 
SOLUTION  
 
                        
 
 
S.NO 
 
CONCENTRATION 
(µg/ml) 
 
 
ABSORBANCE 
1 01 0.049 ± 0.002 
2 02 0.098 ± 0.002 
3 03 0.147 ± 0.003 
4 04 0.194 ± 0.001 
5 05 0.244 ± 0.001 
6 06 0.294 ± 0.002 
7 07 0.343 ± 0.002 
8 08 0.392 ± 0.001 
9 09 0.441 ± 0.001 
10 10 0.492 ± 0.001 
 
n = 3*                                                                       γ - 0.9998923 
 
 
 
 
TABLE 3 
 
 
DRUG CONTENT OF ALL FORMULATIONS  
 
 
 
S.NO FORMULATIONS DRUG CONTENT 
1 F 1 94.75 % 
2 F 2 97.70 % 
3 F 3 97.00  % 
4 F 4 98.70 % 
5 F 5 100.0 % 
6 F 6 99.00 % 
7 F 7 99.70 % 
8 F 8 100.0 % 
9 F 9 99.83 % 
10 F 10 97.10 % 
11 F 11 98.50 % 
12 F 12 98.80 % 
13 F 13 98.90 % 
14 F 14 100.0 % 
15 F 15 97.90 % 
16 F 16 99.50 % 
17 F 17 98.70 % 
18 F 18 98.90 % 
         n = 3*                                                                       
TABLE 4 
 
ENTRAPMENT EFFICIENCY OF ALL FORMULATIONS 
 
CONTAINING 1 % POLYVINYL ALCOHOL 
 
S.NO FORMULATIONS % ENTRAPMENT                    
EFFICIENCY 
1 F 1 23.10 % 
2 F 2 24.60 % 
3 F 3 25.50 % 
4 F 4 26.90 % 
5 F 5 28.10 % 
6 F 6 29.30 % 
7 F 7 21.70 % 
8 F 8 24.80 % 
9 F 9 27.90 % 
10 F 10 29.20 % 
11 F 11 31.10 % 
12 F 12 33.60 % 
13 F 13 42.60 % 
14 F 14 45.10 % 
15 F 15 48.90  % 
16 F 16 52.10 % 
17 F 17 55.50 % 
18 F 18 62.30 % 
       n = 3* 
TABLE 5 
 
ENTRAPMENT EFFICIENCY OF ALL FORMULATIONS 
 
CONTAINING 2 % POLYVINYL ALCOHOL 
 
S.NO FORMULATIONS % ENTRAPMENT                      
EFFICIENCY 
1 F 1 42.40 % 
2 F 2 45.80 % 
3 F 3 62.70 % 
4 F 4 66.00 % 
5 F 5 75.40 % 
6 F 6 88.10 % 
7 F 7 40.50 % 
8 F 8 45.10 % 
9 F 9 48.20 % 
10 F 10 53.70 % 
11 F 11 76.10 % 
12 F 12 79.30 % 
13 F 13 81.40 % 
14 F 14 83.50 % 
15 F 15 84.80  % 
16 F 16 86.90 % 
17 F 17 89.30 % 
18 F 18 92.60 % 
   n = 3* 
 TABLE 6 
 
COMPARISON OF PARTICLE SIZE 
 
 
S.NO CONCENTRATION MEAN PARTICLE 
SIZE 
 
1 1 % Polyvinyl alcohol 10.24 µm 
 
2 2 % Polyvinyl alcohol 50 nm 
 
3 1 % Stearic acid 1.85 µm 
 
4 2 % Stearic acid 895 nm 
 
5 5 % Stearic acid 50 nm 
 
6 10 % Stearic acid 936 nm 
 
7 15 % Stearic acid 1.76 µm 
 
8 20 % Stearic acid 2.30 µm 
 
9 5 % Glyceryl monostearate 53 nm 
 
10 5 % Compritol ATO 888 80 nm 
 
11 20 % Glyceryl monostearate 2.45 µm 
 
12 20 % Compritol ATO 888 2.60 µm 
 
 
 
 
 
 
TABLE 7 
 
RELEASE PROFILE OF SLN FORMULATONS 
 
CONTAINING STEARIC ACID  
 
Time in 
hours 
F 1 F 2 F 3 F 4 F 5 F 6 
0.25 7.50 9.0 12.0 16.2 21.0 21.00 
0.5 9.40 10.7 13.4 17.1 21.2 21.90 
0.75 11.5 13.2 14.8 19.0 22.2 22.90 
1 13.3 13.9 15.9 20.3 23.0 23.80 
1.5 14.5 16.2 16.8 21.5 23.9 24.50 
2 15.9 18.8 17.6 22.7 25.7 25.50 
2.5 18.1 20.6 18.4 24.4 27.7 26.60 
3 19.8 23.3 19.4 24.9 28.6 27.70 
3.5 22.5 25.5 20.6 25.7 29.7 28.40 
4 23.4 27.0 23.3 27.8 30.7 29.20 
4.5 26.4 29.4 25.9 29.1 31.5 30.10 
5 30.3 31.4 26.8 30.6 32.3 30.80 
5.5 31.6 32.9 27.9 31.8 33.6 32.10 
6 34.8 36.6 29.3 32.7 34.1 32.80 
6.5 37.2 38.4 31.3 33.9 34.8 33.20 
7 39.8 39.7 33.1 35.6 35.7 33.80 
7.5 41.5 41.4 34.7 36.6 36.9 34.90 
8 43.2 43.5 36.5 38.3 37.7 35.30 
8.5 44.7 45.7 38.6 39.0 38.8 35.80 
9 46.4 47.1 41.9 40.2 39.8 36.70 
9.5 47.8 48.7 44.6 41.2 41.6 37.70 
10 51.5 50.6 46.9 41.6 42.4 38.30 
10.5 53.9 53.0 48.3 42.1 43.2 39.10 
11 56.3 53.8 49.8 43.0 43.4 39.70 
11.5 57.0 54.7 51.8 44.7 44.0 40.70 
12 59.1 56.0 54.0 45.6 44.5 41.60 
 n = 3*                                                                  
 
 
 
TABLE 8 
 
RELEASE PROFILE OF SLN FORMULATONS 
 
CONTAINING GLYCERYL MONOSTEARATE   
 
Time in 
hours 
F 7 F 8 F 9 F 10 F 11 F 12 
0.25 9.3 10.8 14.8 15.1 16.1 15.5 
0.50 10.5 12.2 15.9 15.8 16.8 16.3 
0.75 13.4 13.2 17.1 16.7 17.6 18.3 
1.0 14.8 14.3 18.1 17.4 18.9 19.5 
1.5 17.5 16.2 19.2 18.4 19.4 20.2 
2.0 18.8 18.4 20.9 19.1 19.8 21.0 
2.5 20.8 20.0 22.3 20.0 20.6 21.9 
3.0 21.6 21.9 23.5 20.6 21.0 22.3 
3.5 25.0 23.7 25.3 21.4 21.6 23.6 
4.0 26.1 24.4 26.6 22.1 21.9 24.3 
4.5 27.1 24.9 27.5 23.2 22.9 24.9 
5.0 28.2 26.8 29.0 23.9 23.6 25.6 
5.5 29.5 27.9 31.4 24.8 24.5 26.4 
6.0 32.3 29.5 32.3 25.8 25.6 27.1 
6.5 33.5 30.2 34.2 27.4 26.9 28.6 
7.0 35.1 31.3 35.4 28.6 27.8 29.1 
7.5 35.8 33.0 36.2 29.4 28.3 29.7 
8.0 36.7 34.5 36.7 31.0 28.7 30.3 
8.5 37.3 35.5 37.5 31.8 29.9 30.9 
9.0 38.0 36.1 38.5 32.6 30.2 31.4 
9.5 38.5 38.1 39.0 33.3 32.3 32.3 
10.0 39.4 39.3 39.8 34.2 33.9 32.6 
10.5 40.1 40.0 40.4 34.8 34.3 33.4 
11.0 41.1 41.4 40.9 36.1 35.2 33.7 
11.5 43.2 42.4 41.3 37.4 36.0 34.4 
12.0 46.4 43.7 42.2 39.1 37.3 35.2 
    n = 3* 
 
 
 
TABLE 9 
 
RELEASE PROFILE OF SLN FORMULATONS 
 
CONTAINING COMPRITOL ATO 888 
 
 
Time in 
hours 
F 13 F 14 F 15 F 16 F 17 F 18 
0.25 9.0 10.0 11.0 14.5 15.2 15.4 
0.5 11.4 11.9 11.8 15.7 16.2 16.2 
0.75 12.5 12.8 13.0 16.3 17.3 17.5 
1 14.1 14.2 14.5 17.2 18.5 18.6 
1.5 15.1 15.2 15.3 18.2 19.3 19.5 
2 16.5 16.7 16.9 19.1 20.8 20.2 
2.5 17.3 18.2 18.3 20.3 20.9 20.5 
3 18.9 19.5 19.9 21.2 21.6 21.0 
3.5 20.3 21.0 20.8 22.3 22.9 21.7 
4 22.4 22.7 21.9 22.9 23.1 22.3 
4.5 23.7 23.6 23.7 23.7 23.9 23.1 
5 25.1 27.5 24.6 24.8 24.6 24.3 
5.5 26.7 28.6 25.7 26.1 25.3 24.3 
6 30.1 30.1 27.7 27.5 26.4 24.6 
6.5 30.8 31.1 28.7 28.6 27.6 25.1 
7 33.8 32.0 30.2 29.4 28.2 25.3 
7.5 35.5 32.6 31.4 31.7 28.9 25.8 
8 37.5 33.7 32.4 32.3 29.6 26.1 
8.5 39.3 34.9 33.3 33.0 30.4 26.3 
9 40.4 36.1 34.1 34.1 31.0 26.4 
9.5 41.7 37.9 34.8 34.3 31.5 26.8 
10 43.2 38.2 35.9 35.0 31.9 26.9 
10.5 44.2 40.0 37.0 35.5 32.4 27.1 
11 45.9 40.7 38.2 36.1 32.8 27.4 
11.5 48.3 42.3 38.6 36.8 33.1 27.8 
12 52.1 44.3 39.1 37.4 33.6 28.1 
 n = 3* 
 
 
TABLE 10 
 
COMPARISON OF BEST FORMULATION WITH PURE DRUG  
TIME in hours F 15 PURE DRUG 
0.25 15.1 16.4 
0.50 15.8 27.3 
0.75 16.7 37.6 
1.0 17.4 54.6 
1.5 18.4 69.3 
2.0 19.1 81.0 
2.5 20 94.3 
3.0 20 99.3 
3.5 21.4 99.1 
4.0 22.1 99.1 
4.5 23.2 - 
5.0 23.9 - 
5.5 24.8 - 
6.0 25.8 - 
6.5 27.4 - 
7.0 28.6 - 
7.5 29.4 - 
8.0 31 - 
8.5 31.8 - 
9.0 32.6 - 
9.5 33.3 - 
10.0 34.2 - 
10.5 34.8 - 
11.0 36.1 - 
11.5 37.4 - 
12.0 39.1 - 
 
 
 
 
 
 
 
 
TABLE 11 
RELEASE KINETICS VALUES OF SLN 
FORMULATIONS 
 
 
 
 
 
 
 
 
S.No Formulation Release Kinetics Values 
  
Zero Order 
Release 
First Order 
Release Higuchi Model 
Korse-Meyer 
Peppas Model 
 
k r2 k (hr-1) r2 k (hr-1) r2 n r2 
1 F 1 1.803 
 
0.811 0.009 
 
0.988 7.5 
 
0.923 0.063 0.908 
   2 F 2 1.939 0.859 0.010 .973 7.8 0.910 0.063 0.811 
3 F 3 2.169 0.900 0.011 0.992 8.6 0.940 0.072 0.811 
4 F 4 2.169 0.900 0.014 0.985 10.7 0.975 0.089 0.842 
5 F 5 2.873 0.951 0.016 0.997 11.4 0.989 0.091 0.779 
6 F 6 3.003 0.934 0.017 0.981 12.1 0.993 0.098 0.806 
7 F 7 1.239 0.655 0.005 0.925 5.4 0.827 0.047 0.982 
8 F 8 1.770 0.819 0.008 0.987 7.3 0.925 0.061 0.912 
9 F 9 2.208 0.895 0.011 0.992 8.9 0.958 0.072 0.837 
10 F 10 2.624 0.947 0.014 0.994 10.5 0.988 0.084 0.785 
11 F 11 2.724 0.955 0.015 0.990 10.8 0.976 0.084 0.759 
12 F 12 3.557 0.985 0.021 0.987 13.8 0.961 0.109 0.676 
13 F 13 1.971 0.771 0.010 0.996 8.3 0.888 0.075 0.911 
14 F 14 2.349 0.832 0.013 0.994 9.7 0.928 0.087 0.879 
15 F 15 2.693 0.903 0.015 0.992 10.9 0.969 0.097 0.849 
16 F 16 3.653 0.966 0.022 0.972 14.0 0.934 0.113 0.633 
17 F 17 4.173 0.980 0.027 0.998 16.4 0.984 0.138 0.700 
18 F 18 4.481 0.990 0.020 0.989 17.3 0.964 0.143 0.642 
TABLE 12 
 
FOURIER TRANSFORM- INFRA RED POSITIONS OF  
 
VARIOUS BOND-VIBRATIONS IN MONTELUKAST SODIUM 
 
 
S.NO BOND WAVENUMBER 
(cm¯1) 
MODE 
1 C=O 3396 Stretch 
 
2 C-H 3058 Stretch 
 
3 C=O 2925 Stretch 
 
4 C=O 1710 Stretch 
 
5 C-C 1610 Stretch 
 
6 C-N 1595 Stretch 
 
7 C-H 1498 Bending 
 
8 C-O 1132 Stretch 
 
9 C-Cl 1068 Stretch 
 
10 C-H 837 Bending 
 
11 C-S 697 Stretch 
 
 
 
 
 
  
 
 
 
TABLE 13 
 
DSC STUDIES: 
 
ENDOTHERMIC PEAKS OF DRUG, LIPIDS AND ITS  
 
PHYSICAL MIXTURES 
 
 
S.NO 
 
NAME OF THE SAMPLE 
 
ENDOTHERMIC PEAKS 
 
1 
 
Montelukast sodium 
 
125 °C 
 
2 
 
Stearic acid 
 
57 °C 
 
3 
 
Glyceryl monostearate 
 
55 °C 
 
4 
 
Compritol ATO 888 
 
60 °C 
 
5 
 
Drug and Stearic acid 
 
125 °C and 57 °C 
 
6 
 
Drug and Glyceryl monostearate 
 
125 °C and 55 °C 
 
7 
 
Drug and Compritol ATO 888 
 
125 °C and 60 °C 
 
 
 
 
 
 
 
TABLE 14 
 
STABILITY STUDIES 
 
PERCENTAGE ENTRAPMENT EFFICIENCY OF ALL 
FORMULATIONS 
 
STORED AT TEMPERATURE 4O±2OC (WEEKS) 
 
 
 
FORMULATION 0 1 2 3 4 5 
F 1 42.40 42.10 42.00 41.80 41.60 41.50 
F 2 45.80 45.30 45.10 45.00 44.80 44.50 
F 3 62.70 62.60 62.50 62.40 62.20 62.10 
F 4 66.00 66.00 65.80 65.70 65.50 65.40 
F 5 75.40 75.10 75.10 75.00 74.80 74.50 
F 6 88.10 87.80 87.70 87.70 87.50 87.10 
F 8 45.10 44.80 44.70 44.50 44.40 44.10 
F 9 48.20 48.00 47.90 47.40 47.30 46.90 
F 10 53.70 53.30 53.20 53.20 53.10 52.90 
F 11 76.10 75.70 75.60 75.40 75.30 75.20 
F 12 79.30 79.00 78.80 78.70 78.60 78.50 
F 13 81.40 81.20 81.10 80.00 80.00 80.00 
F 14 83.50 83.50 83.40 83.20 83.10 83.00 
F 15 84.80 84.70 84.40 84.10 84.10 83.90 
F 16 86.90 86.70 86.60 86.40 86.10 85.50 
F 17 89.30 89.20 89.10 88.70 88.10 87.90 
F 18 92.60 92.50 92.10 91.40 91.10 90.30 
  
 
 
 
TABLE 15 
 
STABILITY STUDIES 
 
PERCENTAGE ENTRAPMENT EFFICIENCY OF ALL 
FORMULATIONS 
 
STORED AT TEMPERATURE 25O± 2OC AND 60 ± 5 % RH 
(WEEKS) 
 
 
 
FORMULATION 0 1 2 3 4 5 
F 1 42.40  42.00 41.50 41.00 40.50 40.10 
F 2 45.80  45.10  44.60 44.20 44.10 43.50 
F 3 62.70  62.40  62.00 61.70 61.20 61.80 
F 4 66.00  65.90  65.60 65.30 65.00 64.30 
F 5 75.40  75.10  75.00 74.30 74.00 73.60 
F 6 88.10  87.80  87.30 87.30 87.10 87.00 
F 8 45.10  43.80  42.70 42.50 41.40 40.10 
F 9 48.20  46.00  46.50 46.10 45.30 44.90 
F 10 53.70  53.00  52.20 52.00 51.10 50.20 
F 11 76.10  75.00  74.30 74.00 73.60 72.10 
F 12 79.30  78.80  77.80 77.10 76.90 75.50 
F 13 81.40  80.60  80.20 79.00 78.30 77.30 
F 14 83.50  82.50  81.60 81.10 80.50 80.40 
F 15 84.80   84.30  82.90 81.10 80.50 80.00 
F 16 86.90  86.80  86.20 86.00 85.10 84.30 
F 17 89.30  88.00  87.10 86.40 86.20 85.80 
F 18 92.60  91.90  90.50 90.00 89.10 89.50 
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 FIGURE 12 
CALIBRATION CURVE OF MONTELUKAST SODIUM IN 0.5 % SLS SOLUTION
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FIGURE 13  
ENTRAPMENT EFFICIENCY OF ALL FORMULATIONS 
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FIGURE 14 
PARTICLE SIZE STUDIES: 
FIGURE SHOWS PARTICLE SIZE DISTRIBUTION OF EMPTY 
SLN CONTAINING 1 % PVA  
 
 
 
 
 
 
 
 
 
 
FIGURE 15 
FIGURE SHOWS PARTICLE SIZE DISTRIBUTION OF EMPTY 
SLN CONTAINING 2 % PVA  
 
 
 
 
 
 
 
 
 
 
 FIGURE 16 
FIGURE SHOWS PARTICLE SIZE DISTRIBUTION OF                      
F 3 (5 % STEARIC ACID) 
 
 
 
 
 
 
 
 
 
  FIGURE 17    
FIGURE SHOWS PARTICLE SIZE DISTRIBUTION OF                
F 9 (5% GLYCERYL MONOSTEARATE) 
 
 
 
 
 
 
 
 
 
FIGURE 18 
FIGURE SHOWS PARTICLE SIZE DISTRIBUTION OF                     
F 15 (5 % COMPRITOL ATO 888) 
 
 
 
 
 
 
 
 
 
FIGURE 19 
FIGURE SHOWS PARTICLE SIZE DISTRIBUTION OF                     
F 6 (20 % STEARIC ACID) 
 
 
 
 
 
 
 
 
 
FIGURE 20 
FIGURE SHOWS PARTICLE SIZE DISTRIBUTION OF                     
F 12 (20 % GLYCERYL MONOSTEARATE 
 
 
 
 
 
 
 
 
 
FIGURE 21 
FIGURE SHOWS PARTICLE SIZE DISTRIBUTION OF                     
F 18 (20 % COMPRITOL ATO 888) 
 
 
 
 
 
 
 
 
 
 
 
 FIGURE 22 
IN-VITRO RELEASE PROFILE OF SLN CONTAINING DRUG AND
1 % LIPID
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Where D: SA –Drug+Stearic acid, D:GMS –Drug+ Glyceryl monostearate and D:COMP – Drug+Compritol. 
 
 
 
 
 
 
 
 
 
FIGURE 23 
IN-VITRO RELEASE PROFILE OF SLN CONTAINING DRUG AND
2 % LIPID
0 5 10 15
0
20
40
60
D:SA
D:GMS
D:COMP
TIME IN HOURS
C
UM
UL
A
TI
V
E 
 
%
 
D
R
UG
 
R
EL
EA
SE
 
Where D: SA –Drug+Stearic acid, D:GMS –Drug+ Glyceryl monostearate and D:COMP – Drug+Compritol. 
 
 
 
 
 
 
 
 
 
 
FIGURE 24 
IN-VITRO RELEASE PROFILE OF SLN CONTAINING DRUG AND
5 % LIPID
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Where D: SA –Drug+Stearic acid, D:GMS –Drug+ Glyceryl monostearate and D:COMP – Drug+Compritol. 
 
 
 
 
 
 
 
 
 
FIGURE 25 
IN-VITRO RELEASE PROFILE OF SLN CONTAINING DRUG AND
10 % LIPID
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Where D: SA –Drug+Stearic acid, D:GMS –Drug+ Glyceryl monostearate and D:COMP – Drug+Compritol. 
 
 
 
 
 
 
 
 
 
FIGURE 26 
IN-VITRO RELEASE PROFILE OF SLN CONTAINING DRUG AND
15 % LIPID
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Where D: SA –Drug+Stearic acid, D:GMS –Drug+ Glyceryl monostearate and D:COMP – Drug+Compritol. 
 
 
 
 
 
 
 
 
 
 
FIGURE 27 
IN-VITRO RELEASE PROFILE OF SLN CONTAINING DRUG AND
20 % LIPID
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Where D: SA –Drug+Stearic acid, D:GMS –Drug+ Glyceryl monostearate and D:COMP – Drug+Compritol. 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 28 
COMPARISON OF IN-VITRO RELEASE PROFILE OF BEST
FORMULATION WITH PURE DRUG
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Where D:COMP – Drug+Compritol. 
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FORMULATIONS AND PURE DRUG
 
 
 
 
 
 
0
20
40
60
80
100
120
PD F 1 F 2 F 3 F 4
C
U
M
.
 
%
 D
R
U
G
 
R
EL
EA
SE
COMPARISON OF RELEASE STUDIES OF ALL
FORMULATIONS WITH  PURE DRUG
FIGURE 29 
 
IN-VITRO RELEASE STUDIES OFALL
 
 
Where PD – Pure drug. 
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FIGURE 30 
 
KINETIC MODELLING OF THE BEST FORMULATION (F 15) 
 
ZERO-ORDER KINTEICS MODEL  FIRST-ORDER KINTEICS MODEL 
 
            
 
 
 
HIGUCHI KINETICS MODEL   KORSE-MEYER PEPPAS MODEL 
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 FIGURE 31 
 
SEM PHOTOGRAPH OF THE BEST FORMULATION (F 15) 
 
 
 
 
 
 
 
 
 
 
 
 FIGURE 32 
 
FTIR SPECTRA OF MONTELUKAST SODIUM 
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FTIR SPECTRA OF STEARIC ACID 
 
 
 
 
 
 
 
 
 
 FIGURE 34 
 
FTIR SPECTRA OF GLYCERYL MONOSTEARATE 
 
 
 
 
 
 
 
 
 
 FIGURE 35 
 
FTIR SPECTRA OF COMPRITOL ATO 888 
 
 
 
 
 
 
 
 
 
 FIGURE 36 
 
FTIR SPECTRA OF DRUG AND STEARIC ACID 
 
 
 
 
 
 
 
 
 
 FIGURE 37 
 
FTIR SPECTRA OF DRUG AND GLYCERYL MONOSTEARATE 
 
 
 
 
 
 
 
 
 
 FIGURE 38 
 
FTIR SPECTRA OF DRUG AND COMPRITOL ATO 888 
 
 
 
 
 
 
 
 
 
 FIGURE 39 
DSC THERMOGRAM OF MONTELUKAST SODIUM 
 
 
FIGURE 40 
DSC THERMOGRAM OF STEARIC ACID 
 
 
 
FIGURE 41 
DSC THERMOGRAM OF GLYCERYL MONOSTEARATE 
 
 
 
FIGURE 42 
DSC THERMOGRAM OF COMPRITOL ATO 888 
 
 
 
FIGURE 43 
DSC THERMOGRAM OF DRUG WITH STEARIC ACID 
 
 
FIGURE 44 
DSC THERMOGRAM OF DRUG WITH GLYCERYL MONOSTERATE 
 
 
FIGURE 45 
DSC THERMOGRAM OF DRUG WITH COMPRITOL ATO 888 
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